

Variants in the proteasome regulator PSMF1 cause a phenotypic spectrum from parkinsonism to perinatal lethality

Received: 14 July 2024

Accepted: 19 March 2026

Published online: 15 April 2026



A list of authors and their affiliations appears at the end of the paper

Dissecting biological pathways highlighted by Mendelian gene discovery has provided critical insights into the pathogenesis of Parkinson's disease (PD) and neurodegeneration. This approach ultimately catalyzes the identification of potential biomarkers and therapeutic targets. Here we identify *PSMF1* as a gene implicated in parkinsonism and childhood neurodegeneration. We find that biallelic *PSMF1* missense and loss-of-function variants co-segregate with phenotypes from early-onset PD to perinatal lethality with neurological manifestations across 18 pedigrees with 25 affected subjects, showing clear genotype-phenotype correlation. *PSMF1* encodes the proteasome regulator PSMF1/hPI31, a highly conserved, ubiquitously expressed partner of the 20S proteasome and neurodegeneration-associated F-box-O 7 and valosin-containing proteins. We demonstrate that *PSMF1* variants may affect proteasomal abundance and assembly, and are associated with alterations of mitochondrial membrane potential, respiration, dynamics and mitophagy in patient-derived fibroblasts. Furthermore, *Drosophila* and mouse models of PI31 loss of function exhibit age-dependent motor impairment, as well as brain-wide mitochondrial membrane depolarization and dopaminergic neurodegeneration in aged flies, and diffuse gliosis in mice. Collectively, our findings unequivocally link defective PSMF1/hPI31 to early-onset parkinsonism and neurodegeneration, and suggest proteasomal and mitochondrial dysfunction as pathogenic contributors.

Parkinson's disease (PD), the second-most prevalent neurodegenerative disorder worldwide, is projected to grow exponentially with no cure currently available^{1,2}. Notably, up to 15% of PD cases are linked to mono- and biallelic pathogenic or risk variants in single genes³. Monogenic forms of PD and parkinsonism have unveiled crucial pathomechanisms that also underpin sporadic forms, highlighting a complex neurobiological network^{1,4}. This involves α -synuclein synthesis and dynamic equilibrium (*SNCA*), degradation of cytoplasmic components and organelles via the autophagy-endolysosomal system (*GBA1*, *LRRK2*, *RAB32*, *VPS35*), proteostasis through the ubiquitin-proteasome system (*PRKN*, *FBXO7*), mitochondrial functions (*PRKN*, *PINK1*, *FBXO7*), oxidative stress response (*DJ-1*) and the regulation of

neuroinflammation (*LRRK2*)^{1,4,5}. Disruption in these pathways culminates in the loss of dopaminergic neurons in the substantia nigra pars compacta, manifesting clinically as parkinsonism^{1,5}. Exploring pathways highlighted by Mendelian gene discovery fosters the identification of biomarkers and development of disease-modifying strategies for PD, as exemplified by *LRRK2* inhibitors^{6–8}.

Perturbations of the ubiquitin-proteasome system and mitochondrial processes are recognized as pivotal, interconnected drivers of neurodegeneration in PD, ultimately contributing to dopaminergic neuron vulnerability through proteotoxicity and bioenergetic failure^{9–13}. Within this framework, *PSMF1*, which encodes the proteasome regulator PSMF1/hPI31^{14,15}, emerges as a key player.

✉ e-mail: f.magrinelli@ucl.ac.uk; francescamagrinelli@gmail.com; k.bhatia@ucl.ac.uk; h.houlden@ucl.ac.uk

PSMF1/hPI31 is a highly conserved 31-kDa protein which is ubiquitously expressed across human tissues^{15,16}. In vitro, PI31 inhibits peptide hydrolysis by the 20S proteasome through its C-terminal proline-rich domain, via either direct binding or competitive binding to the 20S activating particles PA700 and PA28^{15,17}. However, PI31 can also stimulate 26S proteasome-mediated proteolysis in vitro¹⁸. In vivo studies demonstrate a biological function of PI31 in promoting protein breakdown. PI31 can stimulate 26S assembly¹⁹, and inactivation of *PI31* in fruit flies (*Drosophila melanogaster*) and *Psmf1* in mice (*Mus musculus*) causes accumulation of poly-ubiquitinated aggregates, which are exclusive substrates of the 26S proteasome^{18–20}. Furthermore, PI31 promotes proteolysis in *Drosophila*, mouse, yeast and plants^{18,21–23}. Finally, it mediates fast transport of proteasomes between neurosomes and synapses and is required for synapse maintenance and neuronal survival in *Drosophila* and mice^{20,21}. Notably, PSMF1/hPI31 interacts with key proteins implicated in human neurodegeneration. For instance, PSMF1/hPI31 is a high-affinity binding partner of F-box only protein 7 (FBXO7), whose genetic defects cause juvenile-onset PD/parkinsonism²⁴, through their respective N-terminal FBXO7/PI31 (FP) domain²⁵. In human fibroblasts, the ablation of this heterodimer by an *FBXO7* missense variant leads to reduced expression and stability of PSMF1/hPI31 and FBXO7 as well as proteasomal and mitochondrial dysfunction²⁶. Intriguingly, FBXO7 prevents PI31 from proteolytic cleavage in *Drosophila* and mouse, suggesting that FBXO7 loss may cause proteasomal impairment by PI31 inactivation^{18,27}. Additionally, PSMF1/PI31 directly binds valosin-containing protein (VCP)²⁸, whose defective functions are linked to amyotrophic lateral sclerosis, frontotemporal dementia and Huntington disease^{29,30}, with VCP and PSMF1/PI31 acting as in vitro up- and down-regulator of proteasomal activity, respectively²⁸. Finally, *PSMF1* variants have also been associated with Alzheimer's disease^{31,32}.

This study identifies *PSMF1* as a gene implicated in PD, parkinsonism and early human neurodegeneration. By extensive data mining and functional validation, we establish that biallelic *PSMF1* missense and loss-of-function variants cause a phenotypic spectrum ranging from early-onset PD to perinatal lethality with neurological manifestations, with clear genotype-phenotype correlation. We explore the organellar and cellular consequences of PSMF1/hPI31 deficiency in vitro by performing live imaging of mitochondria in patient-derived cultured fibroblasts, and proteasome assays of their protein lysates. Finally, we explore its pathological consequences in vivo and ex vivo in *Drosophila* and mouse models.

Results

Identification of biallelic *PSMF1* variants in affected subjects from 18 ethnically diverse families

In a nonconsanguineous Serbian family (Pedigree A; Fig. 1a) with the male proband (A-II-2) affected by early-onset parkinsonism, patient-parent trio exome sequencing (ES) revealed he was compound heterozygote for one missense variant [c.724 C > G p.(Arg242Gly)] and one splice variant (c.282+2 T > A) in the candidate gene *PSMF1* (NM_006814.5). Through initial data sharing, we identified a consanguineous Turkish family (Pedigree B; Fig. 1a) with two siblings (B-II-3; B-II-4) manifesting with early-onset PD and harboring the same *PSMF1* missense variant detected in Pedigree A in the homozygous state³³. To replicate the association of biallelic *PSMF1* variants with PD/parkinsonism and further delineate *PSMF1*-related disorder, we applied a genotype-first approach by interrogating large next-generation sequencing datasets from collaborative networks and platforms, including Queen Square Genomics (Pedigrees D-I-L-M), several diagnostic and research genetic laboratories worldwide (Pedigrees C-D-E-F-G-H-M-P), 100,000 Genomes Project, UK Biobank (UKB), The Accelerating Medicines Partnership program for Parkinson's disease (AMP-PD), Solve-RD, CENTOGENE (Pedigrees B-D-N-O), GeneDx, Baylor Genetics, Genesis (Pedigree F), ClinVar, VarSome, Lifera Omics

(Pedigree N), GeneMatcher (Pedigrees J-K-Q-R)³⁴. Pedigrees identified from multiple sources were deduplicated.

Biallelic *PSMF1* variants cause a phenotypic spectrum from early-onset PD or parkinsonism to perinatal lethality with neurological manifestations

A total of 25 affected subjects from 18 unrelated families of European, Asian and African ancestry were identified (Fig. 1a). Genotype was determined for all but two individuals (M-II-1, P-II-4; DNA not available), who were included due to striking clinical resemblance to their affected siblings carrying homozygous *PSMF1* variants in the context of parental consanguinity. One aborted fetus (R-II-2) was included based on *PSMF1* variants identified on reanalysis of the ES data from prenatal genetic testing and phenotypic overlap with the proband of Pedigrees P-Q, who died during infancy. Pregnancy losses in Pedigrees O-P-Q were excluded due to insufficient pheno-genotypic information. Clinical features and neuroimages are highlighted in Fig. 1b, c and described in Tables 1–3. Case descriptions are detailed in Supplementary Notes 1.

The cohort comprised 12 males and 13 females. Parental consanguinity was reported in 11 of 18 pedigrees (61.1%). Probands' parents were healthy. Based on the phenotypic features and severity, we distinguished three subgroups across subjects with *PSMF1*-related disorder and recognized clear genotype-phenotype correlation (Fig. 1b).

In Pedigrees A-B-C-D-E-F-G-H-I (Table 1), affected individuals manifested with early-onset PD closely resembling well-established recessive monogenic forms (e.g. *PRKN*, *PINK1*, *DJ-1*, *FBXO7*), or with parkinsonism as the core phenotypic feature. After unremarkable neurodevelopmental milestones, motor symptoms began between the first and fifth decade of life, particularly during late adolescence or the third decade. In this subgroup, parkinsonism was most often accompanied by mild pyramidal tract signs, moderate-severe dysphagia occurring early in the disease course and psychiatric manifestations. Brain MRI was normal or detected minor abnormalities, including mild-to-moderate cerebral or mild cerebellar atrophy (Fig. 1c). Five probands (A-II-2, B-II-3, C-II-3, D-II-2, I-II-3) had markedly abnormal presynaptic dopaminergic imaging (Fig. 1c). In two probands (A-II-2, C-II-3), normal tracer uptake on ¹²³I-metaiodobenzylguanidine (¹²³I-MIBG) myocardial scintigraphy indicates preserved cardiac sympathetic innervation (Fig. 1c). Affected individuals had different degrees of response to dopaminergic treatments and tended to develop early motor and non-motor fluctuations and levodopa-induced dyskinesia. Two probands (D-II-2, E-II-4) underwent bilateral subthalamic nucleus deep brain stimulation associated with good response which was, nevertheless, blurred subsequently by fairly rapid disease deterioration. Three patients (B-II-4, D-II-2, E-II-4) died nearly two decades after symptom onset. All affected individuals in this subgroup harbored *PSMF1* missense variants, either in the homozygous state (Pedigrees B-C-D-E-F-G-H) or in compound heterozygosity with a predicted loss-of-function variant (Pedigrees A-I).

Affected individuals belonging to Pedigrees J-K-L-M (Table 2) presented with miscellaneous movement disorders, encompassing parkinsonism, moderate-to-severe pyramidal tract signs, ataxia or a combination thereof, most often in the context of neurodevelopmental delay and associated with mild-to-moderate intellectual disability, epilepsy and cognitive decline. They exhibited facial or skeletal dysmorphic features. In this subgroup, two probands (J-II-3, K-II-3) had sensorineural hearing loss. Brain MRI almost invariably revealed hypoplasia of the corpus callosum and/or various degrees of cerebral or vermician cerebellar atrophy (Fig. 1c). Four patients (J-II-1, M-II-1, M-II-3, M-II-6; Fig. 1a) died during adolescence because of rapidly progressive neurological deterioration starting early in the second decade of life. All affected individuals within this subgroup carried homozygous *PSMF1* splice variants.




Fig. 1 | Pedigrees and phenotypic features of individuals with biallelic *PSMF1* variants. **a** Pedigrees of *PSMF1* families. Pedigrees of 18 *PSMF1* families are presented, with indication of their ethnicity and the results of segregation analysis of *PSMF1* variants. In the diagrams, males are represented by squares, females by circles, and fetuses by triangles. A diagonal line across a symbol indicates a deceased individual. Fetal sex and gestational age at death (*n* weeks/40 weeks) are reported below their symbol, if available. Consanguineous marriages are denoted by double lines between symbols, while probands are marked with an arrow. Individuals exhibiting a neurological disease phenotype are represented by black filled symbols. Fetuses aborted for undetermined cause (O-II-1, P-II-3, Q-II-1) are represented by a gray filled symbol. Roman numerals indicate generations, whereas Arabic numbers denote individuals within each generation. Variants are referenced to *PSMF1* transcript NM_006814.5 and displayed with different font colors (Fig. 2a and Supplementary Table 1). “WT” designates the *PSMF1* wild-type allele. An asterisk identifies dermal fibroblast donors. “d.” in square brackets indicates the age at death. d = days; w = weeks; y = years. **b** Genotype-phenotype correlation in *PSMF1*-related disorder. Schematic representation of the core phenotypic features associated with biallelic variants in *PSMF1*, with indication of age at onset and main clinical manifestations in subgroups of subjects belonging to the study cohort. Increasingly more severe phenotypes correspond to progressively more

deleterious mutational effects. **c** Neuroimaging and ^{123}I -MIBG myocardial scintigraphy features of *PSMF1*-related disorder. Brain MRI with sagittal T1- or T2-weighted images and axial FLAIR or T2-weighted images of individuals A-II-2 (26 years), F-II-3 (29 years), L-II-1 (12 years), M-II-1 (14 years), M-II-3 (10 years), M-II-6 (4 years) and N-II-1 (3 days of life). Mild-to-moderate enlargement of the cerebral subarachnoid spaces is noted in subjects A-II-2, F-II-3, L-II-1, M-II-1 and M-II-3. Enlargement of the subarachnoid spaces of the superior cerebellar vermis is present in individuals F-II-3, M-II-1 and M-II-3. Additional faint T2/FLAIR-signal alterations are visible in the periventricular white matter in individuals A-II-2, M-II-1, M-II-3 and M-II-6 (thick arrows). There is hypoplasia of the corpus callosum (curved arrows) and small anterior commissure (thin arrows) in subjects F-II-3, L-II-1, M-II-1, M-II-3, M-II-6 and N-II-1. There is lack of myelination of the posterior limbs of the internal capsules in patient N-II-1 (dashed arrows), associated with foci of T2 hyperintensity at the level of the putamina. DaTscan images of subjects A-II-2, B-II-3, C-II-3 and I-II-3 reveal a severely reduced tracer uptake in the striatum bilaterally, characterized by complete loss of the typical “comma-shaped” appearance and increased background activity (grade 1, “burst striatum” pattern)¹⁰⁶. ^{123}I -MIBG myocardial scintigraphy measured 15 min (early registration) and 4 h (late registration) after intravenous ^{123}I -MIBG application was normal in proband C-II-3 (32 years). ^{123}I -MIBG = ^{123}I -metaiodobenzylguanidine.

The third subgroup includes affected subjects from Pedigrees N-O-P-Q-R (Table 3), who presented with severe neurological manifestations since prenatal development, including arthrogryposis multiplex congenita, abnormal fetal movements (suspected for in utero seizures), epilepsy, profound developmental delay, limb spasticity,

severe respiratory insufficiency and poor feeding. Death occurred during infancy in all affected individuals within this subgroup, except for proband N-II-1, who is currently 21 months old and dependent on full medical support for all vital functions, and proband O-II-2, who is currently 18 months old and had severe global developmental delay

Table 1 | Phenotypic features and genotype of 10 subjects with *PSMF1*-related disorder belonging to pedigrees A-B-C-D-E-F-G-H-I

Pedigree Individual	Pedigree A A-II-2	Pedigree B B-II-3	Pedigree C C-II-3	Pedigree D D-II-2	Pedigree E E-II-4	Pedigree F F-II-3	Pedigree G G-II-3	Pedigree H H-II-1	Pedigree I I-II-3	
Sex/Curent age	M/30 yrs	F/40 yrs	M/34 yrs	M/ Deceased (44 yrs)	F/ Deceased (67 yrs)	M/35 yrs	F/36 yrs	F/32 yrs	M/20 yrs	
Ethnicity	Serbian	Turkish	Romanian	Spanish	French	Turkish	Turkish	Turkish	Croatian	
Parental consanguinity	No	Yes	No	Yes	No	Yes	Yes	Yes	No	
Family history	Unremarkable	One brother affected (B-II-4)	One sister affected (B-II-3)	Paternal grand-father and maternal grandmother with PD; mother had 6 siblings who died during childhood	Unremarkable	Unremarkable	Unremarkable	Unremarkable	Paternal grandmother and her two brothers with tremor and dementia; MDD and child mortality in several relatives in the maternal line; epilepsy in multiple family members	
Core phenotype	Parkinsonism	Parkinsonism	Parkinsonism	Parkinsonism	Parkinsonism	Parkinsonism	Parkinsonism	Parkinsonism	Parkinsonism	
Age at onset	21 yrs	16 yrs	18 yrs	29 yrs	27 yrs	48 yrs	19 yrs	15 yrs	3 yrs	
Symptom at onset	Bradykinesia, dysphagia, anxiety	Right hand tremor	Right hand tremor	Right upper limb rigidity, right hand tremor and reduced dexterity	Micrographia	Left upper limb tremor	Hand tremor, left foot dragging, anxiety	Bradykinesia, right hand tremor, right foot dystonia	Clumsiness, frequent falls without fall reflex	
Neurological manifestations										
Motor features	Parkinsonism (bradykinesia, rigidity, postural instability) Eye movement abnormalities Dysarthria Gait festination. Balance difficulty Pyramidal signs (hyperreflexia, Babinski sign, ankle clonus) Mild cerebellar signs	Parkinsonism (bradykinesia, rigidity, rest tremor, postural instability) Dysarthria Freezing of gait Balance difficulty	Parkinsonism (bradykinesia, rigidity, rest tremor, postural instability) Blepharospasm Dysarthria Postural and kinetic tremor Freezing of gait to tiptoe walking Pyramidal signs (hyperreflexia)	Parkinsonism (bradykinesia, rigidity, postural instability) Blepharospasm (hyperreflexia) Freezing of gait Falls Tiptoe walking	Parkinsonism (bradykinesia, rigidity, rest tremor, postural instability) Restless leg syndrome Freezing of gait	Parkinsonism (bradykinesia, rigidity, rest tremor, postural instability) Postural tremor (hyperreflexia, ankle clonus)	Parkinsonism (bradykinesia, rigidity, rest tremor) Postural and kinetic tremor Falls Mild pyramidal signs (hyperreflexia of the patellar tendon reflex)	Tremulous segmental dystonia Parkinsonism (bradykinesia, rigidity, rest tremor) Action tremor Blepharospasm Hyperreflexia Myoclonus Frequent episodes of freezing Lower limb muscle hypotrophy Pes cavus Ankle joint contractures	Parkinsonism (bradykinesia, rigidity, rest tremor) Action tremor Blepharospasm Hyperreflexia Myoclonus Frequent episodes of freezing Lower limb muscle hypotrophy Pes cavus Ankle joint contractures	
Non-motor features	Somnoliquy Dysphagia Emotional lability Occasional urinary incontinence Constipation Involuntary vocalizations	Insomnia Dysarthria Dysphagia Emotional lability	RBD Dysarthria Dysphagia Emotional lability Urinary urgency Constipation	Mild dysphagia	Dysphagia Dysarthria Emotional lability Constipation Insomnia	Urinary urgency Vivid dreams Fatigue Frontal syndrome	Dysphagia Somnoliquy	Insomnia Emotional lability Constipation	Dysphagia for fluids Orthostatic hypotension Emotional lability	Dysarthria Dysphagia Constipation (pseudo-obstruction) Xerostomia Hypohidrosis

Table 1 (continued) | Phenotypic features and genotype of 10 subjects with PSMF1-related disorder belonging to pedigrees A-B-C-D-E-F-G-H-I

Pedigree	Pedigree A	Pedigree B	Pedigree C	Pedigree D	Pedigree E	Pedigree F	Pedigree G	Pedigree H	Pedigree I
Response to treatment	Mild-to-moderate response to LD Early-onset LD-induced dyskinesia	Mild-to-moderate response to LD Early-onset LD-induced dyskinesia	No response to LD Mild response to DA Good response to recent LD initiation	Initial good response to LD Severe motor fluctuations and LD-induced dyskinesia Initial good response to DBS	Initial good response to LD Severe motor fluctuations and LD-induced dyskinesia Initial good response to DBS	Moderate response to LD LD-induced dyskinesia	Response to LD only in the early phase Mild response to DA	Poor response to LD	Initial good response to LD
Other clinical manifestations	Anxiety/Phobias Obesity Glucose intolerance Osteopenia COPD	Severe depression Anxiety Auditory hallucinations	Dry eye Auditory hallucinations	N/A	N/A	Anxiety Obesity Insulin resistance Systemic hypertension Early alopecia	Anxiety ICD (after Cabergoline initiation)	Depression GERD	Anxiety Obsessive-compulsive disorder Delayed puberty Kyphoscoliosis Fatigue Excessive daytime sleepiness
Brain MRI (age)	Mild cerebral atrophy, faint T2 hyperintensity in the posterior periventricular WM (24 yrs)	Normal	Mild atrophy of the inferior cerebellar vermis	Normal	Normal	Mild-to-moderate cerebral atrophy, thin CC, small AC, small midbrain, mild atrophy of superior cerebellar vermis (29 yrs)	Normal (29 yrs)	Mild cerebellar cortical atrophy	Retrocerebellar cyst
Other instrumental investigations	DaTscan: abnormal Myocardial MIBG: normal DEXA: osteopenia	EEG: normal EMG/NCS: normal	EEG: normal EMG/NCS: normal Muscle biopsy: normal	FDOPA-PET: abnormal FDG-PET: temporal hypometabolism	N/A	US: no organomegaly Ophthalmological assessment: normal Normal CK, lactate, pyruvate, copper, caeruloplasmin and 24-h urinary copper excretion	Brain perfusion SPECT: reduced perfusion in the left thalamus ICD: prolonged latency Brain MRS: normal Muscle MRI: atrophy of gluteal muscles, with increased muscle fat Spine X-ray: scoliosis DEXA: severe osteopenia	EEG/Video EEG: normal	DaTscan: abnormal Low testosterone level EEG: diffuse theta activity VEP: prolonged latency Brain MRS: normal Muscle MRI: atrophy of gluteal muscles, with increased muscle fat Spine X-ray: scoliosis DEXA: severe osteopenia
Genotype PSMF1 (NM_006814.5)	C-HET c.724 C > G p.(Arg242Gly) c.282+2 T > A	HOM c.724 C > G p.(Arg242Gly)	HOM c.724 C > G p.(Arg242Gly)	HOM c.724 C > T p.(Arg242Cys)	HOM c.725 G > A p.(Arg242His)	HOM c.157 C > A p.(Leu53Met)	HOM c.157 C > A p.(Leu53Met)	HOM c.682 C > G p.(Leu228Val)	C-HET c.724 C > G p.(Arg242Gly) c.691 C > T p.(Arg231*)

AC anterior commissure, C-HET compound heterozygote, CC corpus callosum, CK creatine kinase, COPD chronic obstructive pulmonary disease, DA dopamine agonist(s), DBS deep brain stimulation; DEXA dual energy X-ray absorptiometry (bone density scan); EEG electroencephalogram, EMG electromyography, F female; FDG ¹⁸F-fluorodeoxyglucose, FDOPA ¹⁸F-fluorodopa; GERD gastroesophageal reflux disorder, HOM homozygote, ICD impulse control disorder, LD levodopa, M male, MDD motor developmental delay, MIBG ¹²³I-metaiodobenzylguanidine scintigraphy; MRI magnetic resonance imaging; MRS magnetic resonance spectroscopy; N/A not applicable or not available, NCS nerve conduction study, PD Parkinson's disease, PET positron emission tomography, RBD REM sleep behavior disorder; SPECT single-photon emission computed tomography, US ultrasound; VEP visual evoked potentials, WM white matter, yrs years.

Table 2 | Phenotypic features and genotype of 9 subjects with *PSMF1*-related disorder belonging to pedigrees J-K-L-M

Pedigree Individual	Pedigree J		Pedigree K		Pedigree L		Pedigree M		
	J-II-1	J-II-3	K-II-3	L-II-1	L-II-3	L-II-4	M-II-1	M-II-3	M-II-6
Sex/Current age	F/Deceased (19 yrs)	M/16 yrs	M/21 yrs	F/13 yrs	F/8 yrs	F/6 yrs	F/Deceased (15 yrs)	F/Deceased (16 yrs)	M/Deceased (15 yrs)
Ethnicity	Chinese	Chinese	Arab Israeli	Pakistani	Pakistani	Pakistani	Arab Jordanian	Arab Jordanian	Arab Jordanian
Parental consanguinity	No	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Family history	One brother affected (J-II-3)	One sister affected (J-II-1)	Unremarkable	Two siblings affected (L-II-3, L-II-4)	Two siblings affected (L-II-1, L-II-4)	Two siblings affected (L-II-1, L-II-3)	Two siblings affected (M-II-3, M-II-6)	Two siblings affected (M-II-1, M-II-6)	Two siblings affected (M-II-1, M-II-3)
Core phenotype	Parkinsonian-pyramidal syndrome	Spastic-ataxia syndrome	DD with CC agenesis	DD with CC hypoplasia	DD with CC hypoplasia	DD with CC hypoplasia	Parkinsonian-pyramidal syndrome with CC hypoplasia	Parkinsonian-pyramidal syndrome with CC hypoplasia	Parkinsonian-pyramidal syndrome with CC hypoplasia
Age at onset	5 yrs	2 yrs	Early childhood	Early childhood	Early childhood	Early childhood	12 yrs	10 yrs	Infancy
Symptom at onset	Limb spasticity	Limb spasticity	GDD	GDD	SLDD	GDD	Memory and attentional deficits	Memory and attentional deficits	Epilepsy
Neurological manifestations									
Motor features	Parkinsonism Pyramidal signs (spasticity, hyperreflexia) Strabismus Ataxia	MDD Pyramidal signs (spasticity, hyperreflexia) Ataxia	Global hypokinesia Clumsiness Mild hypotonia	Hypokinesia Broad-based gait Talipes	Hypokinesia	Hypokinesia Talipes	Hypokinesia Pyramidal tract signs	Hypokinesia Pyramidal tract signs	Hypokinesia Pyramidal tract signs
Non-motor features	Mild intellectual disability Dysphagia	Borderline intellectual functioning Sensorineural hearing loss Dysphagia	Intellectual disability Chronic headache Sensorineural hearing loss Epilepsy	Intellectual disability Dysarthria Epilepsy Anxiety Behavioral issues	Intellectual disability Dysarthria	Intellectual disability Dysarthria	Epilepsy Cognitive decline Dysphagia	Epilepsy Cognitive decline Anarthria Dysphagia	Epilepsy Cognitive decline Dysphagia Startle response
Response to treatment	N/A	N/A	N/A	Partial response to LEV Good response to CBZ and VPA	N/A	N/A	N/A	Partial response to CBZ and VPA	Unspecified response to CBZ
Other clinical manifestations	Microcephaly Behavioral issues Asthma Obesity Short stature with skeletal deformity Urinary issues	GERD Behavioral issues Systemic hypertension Obesity Obstructive sleep apnea Liver issues	DDH Dysmorphic features Osteoporosis with recurrent fractures Small joint swelling and deformities	Microcephaly Dysmorphic features Delayed tooth eruption Overweight Constipation	Microcephaly Dysmorphic features	Microcephaly Dysmorphic features Overweight Constipation	Dysmorphic features	Dysmorphic features	Dysmorphic features Obesity
Brain MRI (age)	Atrophy of cerebral hemispheres, basal ganglia, thalami, brainstem and cerebellum, with mineralization of the lentiform nuclei	Mild T2 signal alterations in the anterior midbrain bilaterally	CC agenesis, malformation of the left cerebellar hemisphere, cerebellar vermis hypoplasia, arachnoid cyst	Moderate cerebellar atrophy, thin CC (12 yrs)	N/A	N/A	Progressive mild-to-moderate cerebellar atrophy, CC hypoplasia, small AC, faint periventricular T2 signal alterations, mild superior cerebellar vermis atrophy (13 and 14 yrs)	Moderate cerebellar atrophy, CC hypoplasia, small AC, faint periventricular T2 signal alterations, mild superior cerebellar vermis atrophy (10 yrs)	CC hypoplasia, small AC, faint posterior periventricular T2 signal (4 yrs)

Table 2 (continued) | Phenotypic features and genotype of 9 subjects with PSMF1-related disorder belonging to pedigrees J-K-L-M

Pedigree	Pedigree J	Pedigree K	Pedigree L	Pedigree M
Other investigations	N/A	Muscle biopsy and enzymology: normal	EEG: multifocal epileptiform discharges	Sleep EEG (age 14 yrs): general disorganization of brain electrical activity without epileptiform discharges
Genotype PSMF1 (NM_006814.5)	HOM c.282+5 G > A	HOM c.605+1 G > A	HOM c.764+5 G > A	N/A
	HOM c.282+5 G > A	HOM c.605+1 G > A	HOM c.764+5 G > A	HOM c.764+5 G > A

AC anterior commissure, CBZ carbamazepine, CC corpus callosum, DD developmental delay, DDH developmental dysplasia of the hip, DEXA dual energy X-ray absorptiometry (bone density scan), EEG electroencephalogram, F female, GDD global developmental delay, GERD gastroesophageal reflux disorder, HOM homozygote, LEV levetiracetam, M male, MDD motor developmental delay, MRI magnetic resonance imaging, N/A not applicable or not available, SLDD speech and language developmental delay, US ultrasound, VPA valproic acid; yrs/years.

and is fed by nasogastric tube (Supplementary Notes 1). Agenesis or hypoplasia of the corpus callosum was detected in three probands (N-II-1, P-II-5, R-II-2; Fig. 1c). A history of pregnancy losses (O-II-2, P-II-3, Q-II-1) preceding the index case was reported in three of these pedigrees (Fig. 1a). All affected subjects in this subgroup had biallelic *PSMF1* loss-of-function variants, of which at least one predicted to cause complete loss of function.

Validation and functional analysis of 14 missense and loss-of-function variants in *PSMF1*

We detected 14 different *PSMF1* mutant alleles, including five missense and nine loss-of-function variants (six splice, one nonsense, one start-loss and one frameshift; Figs. 1a and 2a). Variant pathogenicity predictions and computational analysis are detailed in Supplementary Table 1. In all subjects with genomic DNA available, segregation analysis confirmed that biallelic *PSMF1* variants co-segregated with neurological disease phenotypes. Moreover, parents of affected individuals harbored one heterozygous *PSMF1* variant, and unaffected siblings of affected subjects were either heterozygotes for one *PSMF1* mutant allele or homozygotes for the *PSMF1* wild-type allele (Fig. 1a). Among 23 affected subjects with genotype available, 19 were homozygotes and 4 were compound heterozygotes for *PSMF1* variants (Fig. 1a).

All *PSMF1* variants identified in the families were absent or ultra-rare in the heterozygous state and not reported in the homozygous state in gnomAD³⁵, except for the missense variant c.725 G > A p.(Arg242His), which had low frequency and four homozygous entries in gnomAD v4.1.0 (Supplementary Table 1). Interestingly, this mutant allele was detected in homozygosity in proband E-II-4, who exhibited the latest PD onset (48 years) among individuals in this study cohort. This may explain the presence of this *PSMF1* variant in gnomAD v4, a reference dataset primarily composed of individuals not selected for severe (pediatric) Mendelian disease, which could reflect its late-onset presentation and/or incomplete penetrance. Variant frequencies in other population and disease datasets, including 100,000 Genomes Project, UKB, All of Us Public Data Browser, and Queen Square Genomics are detailed in Supplementary Table 1.

PSMF1 missense variants identified in this study showed strong evolutionary conservation across species down to invertebrates (Fig. 2b and Supplementary Table 1a). All *PSMF1* non-splice variants were predicted with a damaging effect according to most in silico prediction tools (Supplementary Table 1a). All *PSMF1* non-frameshift variants had a Combined Annotation Dependent Depletion v1.7 Phred score greater than or equal to 22.4 (CADD Phred range: 22.4–37), placing them among the top -0.6% most deleterious substitutions predicted in the human genome. Pathogenicity prediction tools such as PolyPhen2, SIFT4G, PROVEAN and MutationTaster predicted the functional impact of all *PSMF1* missense variants to be damaging/deleterious in most cases. In silico splice predictions of six *PSMF1* splice variants using six computational tools (SpliceSiteFinder-like, MaxEntScan, NNSPLICE, GeneSplicer, SpliceAI, and AbSplice) unanimously indicated reduction or complete abolishment of native splice donor sites according to most tools (Supplementary Table 2b).

Five *PSMF1* variants were detected in more than one family [Pedigrees A-B-C-I: c.724 C > G p.(Arg242Gly); Pedigrees F-G: c.157 C > A p.(Leu53Met); Pedigrees I-N-O: c.691 C > T p.(Arg231*); Pedigrees L-M: c.764+5 G > A; Pedigrees P-R: c.1A > T; Fig. 1a]. Specifically, the missense variant c.724 C > G p.(Arg242Gly) recurred in four families either in the compound heterozygous (Pedigrees A-I) or homozygous (Pedigrees B-C) state. Furthermore, the missense variant c.724 C > T p.(Arg242Cys) detected in Pedigree D involved the same nucleotide as the previous mutant allele. Finally, the missense variant c.725 G > A p.(Arg242His) affected the same amino acid residue as the two previous mutant alleles. Intriguingly, although *PSMF1* variants were distributed across the gene (Fig. 2a), three different *PSMF1* variants

Table 3 | Phenotypic features and genotype of 6 subjects with PSMF1-related disorder belonging to pedigrees N-O-P-Q-R

Pedigree Individual	Pedigree N N-II-1	Pedigree O O-II-2	Pedigree P P-II-4	Pedigree Q Q-II-3	Pedigree R R-II-2
Sex/Current age	F/21 mos	F/18 mos	M/Deceased (1 mo)	F/Deceased (12 mos)	M/Deceased (6 wks)
Ethnicity	Saudi	Pakistani	Syrian	Syrian	Nigerian/Czech
Parental consanguinity	Yes	Yes	Yes	No	No
Family history	Unremarkable	Mother had one miscarriage (GA 12 wks)	Mother had one pregnancy loss (unspecified GA); one brother similarly affected (P-II-5)	Mother had one miscarriage (GA 21 wks)	Unremarkable
Core phenotype	Arthrogryposis with CC hypoplasia	Arthrogryposis	Arthrogryposis	Arthrogryposis with CC agenesis	Arthrogryposis with CC agenesis
Age at onset	Prenatal	Prenatal	Prenatal	Prenatal	Prenatal
Symptom at onset	N/A	N/A	N/A ^a	N/A	N/A
Neurological manifestations					
Motor features	Arthrogryposis Limb spasticity Increased jitteriness GDD	Arthrogryposis Neck and truncal hypotonia Limb spasticity with distal dystonia Pyramidal signs (hyperreflexia, Babinski sign) Dystonic spasms GDD Eye movement abnormalities (nystagmus)	N/A ^a	Myoclonus Arthrogryposis Limb spasticity Truncal hypotonia GDD	Arthrogryposis
Non-motor features	GDD	Sensorineural hearing loss Dysphagia GDD	N/A ^a	Epilepsy Dysphagia GDD Late-stage unresponsiveness to visual and tactile stimuli	Abnormal fetal movements (in utero seizures?)
Response to treatment	N/A	N/A	N/A ^a	Poor response to ASM	N/A
Other clinical manifestations	Microcephaly Dysmorphic features Short stature Poor feeding at birth/Failure to thrive Respiratory insufficiency Recurrent respiratory infections PEG-fed and mechanically ventilated	Failure to thrive GI dysfunction (GER, constipation) Recurrent infections Sleep disturbances	N/A ^a	Hypotrophic newborn Respiratory insufficiency Progressive GI dysfunction (constipation, gastric atony, GER, ileus) Disturbed temperature regulation	Fetal growth restriction Congenital anomalies
Brain MRI (age)	CC hypoplasia, absent myelination within the posterior portion of the internal capsule, multiple foci of T2 hyperintensity within the lentiform nuclei (3 days)	Parenchymal atrophy with dilated ventricles (8 mos)	N/A ^a	CC hypoplasia, hypomyelination, progressive cerebral atrophy, subdural hygromas (2 and 6 mos)	N/A

Table 3 (continued) | Phenotypic features and genotype of 6 subjects with PSMF1-related disorder belonging to pedigrees N-O-P-Q-R

Pedigree	Pedigree N	Pedigree O	Pedigree P	Pedigree Q	Pedigree R
Other investigations	EEG: normal Postnatal abdominal US: normal Ophthalmological assessment: bilateral retinal pigmentary changes, maculopathy and optic nerve atrophy	Prenatal US: intrauterine growth retardation ECG: normal Normal plasma lactate	N/A ^a	Prenatal US: polyhydramnios, clenched fists, clubfoot Neonatal head and spine US: reduced gyration, low-lying conus medullaris/tethered cord EEG: pathological pattern Postnatal echocardiography: ASD type II with left-right shunt Spine MRI: low-lying conus medullaris	Prenatal US (GA 20 ^{1/7} wks): normal. Prenatal US (GA 31 ^{7/7} wks): polyhydramnios, suspected CC agenesis, small stomach. Prenatal US (GA 35 wks): fetal growth restriction, abnormal fetal movements, CC agenesis, intracerebral cyst, arthrogryposis, thickened myocardium, small stomach, left hydronephrosis and hydroureter. QF-PCR: negative. CGH: negative.
Genotype <i>PSMF1</i> (NM_006814.5)	HOM c.691 C > T p.(Arg231*)	HOM c.691 C > T p.(Arg231*)	N/A ^a	C-HET c.101del p.(Gly34Valfs*47) c.129+2 T > C	C-HET c.365+2 T > C c.1 A > T

ASD atrial septal defect; ASM anti-seizure medication(s); C-HET compound heterozygote; CC corpus callosum; CGH comparative genomic hybridization; CTO cardiotocography; EEG electroencephalogram; F female; GA gestational age; GDD global developmental delay; GER gastroesophageal reflux; GI gastrointestinal; HOM homozygote; M male; mo(s) month(s); MRI magnetic resonance imaging; N/A not applicable or not available; PEG percutaneous endoscopic gastrostomy; QF-PCR quantitative fluorescence polymerase chain reaction; US ultrasound; wks weeks.


^aClinical details not available (P-II-4 reported with a phenotype similar to his sister P-II-5).

detected in a total of six families with PD/parkinsonism (Pedigrees A-B-C-D-E-I) involved the p.Arg242 residue, which could therefore represent a “hotspot codon”. Among splice variants, two were contiguous (c.282+2 T > A in Pedigree A; c.282+5 G > A in Pedigree J). The nonsense variant c.691 C > T p.(Arg231*) recurred in three families either in the compound heterozygous (Pedigree I) or homozygous (Pedigrees N-O) state.

Autozygosity mapping. Given the apparent autosomal recessive inheritance mode of *PSMF1*-related disorder and the high prevalence of consanguineous pedigrees in our cohort, we performed autozygosity mapping to guide variant filtering and investigate potential alternative molecular diagnoses. Using AutoMap³⁶ with default parameters (including a minimum ROH size threshold ≥ 1 Mb), we identified that the *PSMF1* locus fell within a region of homozygosity (ROH) in affected individuals carrying homozygous *PSMF1* variants who were born to consanguineous parents (Pedigrees B-D-F-G-H-K-L-M-N-O-P) and in the proband C-II-3, despite no reported parental consanguinity (Supplementary Fig. 1). In contrast, no ROH encompassing *PSMF1* was detected by AutoMap in their unaffected family members with ES data available, nor in probands E-II-4 and J-II-1. However, in proband E-II-4, additional analysis for ROH ≥ 0.01 Mb revealed a 300-kb homozygous block including *PSMF1*. No ROH on chromosome 20 was found in proband J-II-3 or her affected sister J-II-1 (Supplementary Fig. 1). Importantly, across all affected individuals harboring homozygous *PSMF1* variants, we did not identify any additional homozygous pathogenic variants or strong candidate variants within the ROHs that could account for the clinical phenotype observed, unless otherwise specified (Supplementary Notes 1).

Haplotype analysis. Haplotype analysis of the *PSMF1* missense variant c.724 C > G p.(Arg242Gly), detected in homozygosity in three affected individuals from two families of different geographic origins (Turkey: B-II-3, B-II-4; Romania: C-II-3), revealed distinct patterns of flanking variants (Supplementary Fig. 2). Similarly, analysis of the *PSMF1* splice variant c.764+5 G > A, identified in homozygosity in the proband of two unrelated families from different regions (Pakistan: J-II-1; Jordan: K-II-6), also showed differing haplotype backgrounds (Supplementary Fig. 2b). Finally, analysis of the *PSMF1* nonsense variant c.691 C > T p.(Arg231*), which was detected in the homozygous state in two affected individuals from geographically distant countries (Saudi Arabia: N-II-1; Pakistan: O-II-2), again showed different patterns of flanking variants (Supplementary Fig. 2c). In these analyses, the resolution of ES data is not enough to conclude whether this variant might have been inherited from a very ancient common ancestor. In contrast, haplotype analysis of the *PSMF1* missense variant c.157 C > A p.(Leu53Met), found in homozygosity in probands from two unrelated Turkish families from the Black Sea region (F-II-3, G-II-3), revealed a shared homozygous block of 2.78 Mb. We hypothesized this shared genomic region to be an identity-by-descent haplotype and used the ExHap tool³⁷ to calculate the age of the most recent common ancestor (MRCA). We deduced that the *PSMF1* variant c.157 C > A p.(Leu53Met) is a founder variant that emerged between 720 to 556 years ago (Supplementary Fig. 2d).

In silico modeling of *PSMF1* missense variants. To assess the functional consequences of putative pathogenic *PSMF1* missense variants, modeling of the three-dimensional organization of the PSMF1/hPI31-FBXO7 heterotetrameric complex was carried out using AlphaFold 3 (Supplementary Fig. 3)³⁸. While the p.Leu228 and p.Arg242 residues are located in PSMF1/hPI31 regions with low-confidence structural prediction, the p.Leu53 residue sits directly on the interface between PSMF1/hPI31 monomers within the complex, forming hydrogen bonds with p.Val6 and p.Ala9 (Fig. 2c). Substitution of methionine for the leucine at codon 53 likely disrupts these



interactions, weakening the quaternary structure of the predicted heterotetramer. Hence, the PSMF1/hPI31 variant p.Leu53Met detected in Pedigrees F-G (Fig. 1a) could perturb the function of the complex, acting as a loss-of-function variant. Further in vitro and cellular studies are required to test the impact of the p.Leu53Met variant, as well as to gain insight into the effect of coding variants in the C-terminal domain of PSMF1/hPI31.

Functional characterization of PSMF1 variants. RNA sequencing (RNA-seq). In Pedigree A, fibroblast RNA-seq with transcript visualization through Integrative Genomics Viewer (IGV) and analysis through the Detection of RNA Outlier Pipeline (DROP) revealed partial intron retention in transcripts with the PSMF1 splice variant c.282+2T>A, which the proband (A-II-2) and his mother (A-I-2) harbored in the heterozygous state (Figs. 1a and 2d). In proband A-II-2, who is a

Fig. 2 | Location, computational analyses and functional characterization of *PSMF1* variants. **a** Schematic of *PSMF1* and its protein product with location of 14 variants identified in this study and their effect. Upper part. Chromosome 20 showing position of *PSMF1* on 20p13. The chromosome ideogram was adapted from resources provided by Ensembl¹⁰⁷. Middle part. Schematic of *PSMF1* with variants identified in the human disease gene discovery study cohort. Introns are not to scale. Exon numbers are according to the canonical transcript (NM_006814.5). Lower part. Schematic of *PSMF1*/hPI31 protein with amino acid changes linked to disease (reference sequence NP_006805.2). Black labels below individual *PSMF1* variants guide to corresponding panels of (b–g), where computational or functional characterization of these variants is presented. **b** Interspecies alignment showing strong evolutionary conservation of the amino acids affected by the *PSMF1* missense variants identified in this study across species, down to invertebrates. **c** Localization of the p.Leu53 residue within the *PSMF1*/hPI31–*PSMF1*/hPI31 homotetramer crystal structure, revealing a role for this residue in *PSMF1*/hPI31 homodimerization. The residue p.Leu53 is involved in the *PSMF1* variant detected in Pedigrees F–G (Fig. 1a and Supplementary Fig. 3). Image derived from PDB 4OUH using ChimeraX. **d** RNA sequencing. Integrative Genomics Viewer (IGV) screen captures showing results of RNA sequencing for Pedigree A (upper panels), Pedigree J (left lower panel) and probands L-II-4 and M-II-6

(right lower panel). For transcripts with *PSMF1* splice variants c.282+2 T > A (A-I-2, A-II-2), c.282+5 G > A (J-I-1, J-I-2, J-II-3), and c.764+5 G > A (L-II-4, M-II-6), IGV enables visualization of (partial) intron retention. **e** Minigene (splicing) assays. Left panel. Agarose gel of the RT-PCR from the minigene cDNA. Middle panel. Splicing schematic of the NM_006814.5(*PSMF1*):c.365+2 T > C variant showing intron retention with stop codon sequence marked. Right panel. Splicing assay of the NM_006814.5(*PSMF1*):c.605+1 G > A variant shows exon skipping. **f** *PSMF1*/hPI31 immunoblots for human primary dermal fibroblasts from available probands, unaffected relatives and healthy controls indicating loss of *PSMF1*/hPI31 immunoreactivity in most affected individuals. Immunoblots for non-targeting siRNA and *PSMF1*/hPI31 siRNA KD SH-SY5Ys shown alongside indicate specificity of the anti-*PSMF1*/hPI31 antibody used (*N* = 1). **g** Western blot to functionally characterize the start-loss variant NM_006814.5(*PSMF1*):c.1 A > T. Protein lysates (30 µg) from HepG2 cells, and either control or proband (P-II-5) fibroblasts were analyzed by Western blotting using a polyclonal anti-*PSMF1*/hPI31 antibody. HepG2 cells express *PSMF1*/hPI31 at high levels. Control but not proband fibroblasts express *PSMF1*/hPI31 (*N* = 1). β-actin expression was used as loading control. C-Het compound heterozygote; Het heterozygote; Hom homozygote; *N* independent experiment; siRNA KD small interfering RNA knockdown. Source data are provided as a Source Data file.

compound heterozygote for the *PSMF1* variants c.724 C > G p.(Arg242Gly) and c.282+2 T > A, visualization of RNA-seq reads at nucleotide position 724 revealed a wild-type to missense nucleotide ratio of 11%:89%. This skewed ratio suggests nonsense-mediated mRNA decay (NMD) of the transcript derived from the allele carrying the splice variant, leading to relative enrichment of the transcript harboring the missense variant (Figs. 1a–2d). *PSMF1* mRNA was not detected as aberrant expression (AE) or aberrant splicing (AS) outlier in these individuals. In Pedigree J, fibroblast RNA-seq of the proband (J-II-3) and whole-blood RNA-seq of his parents (J-I-1, J-I-2) with transcript visualization by IGV showed intron retention in transcripts with the *PSMF1* splice variant c.282+5 G > A, which was detected in the homozygous state in the proband and in the heterozygous state in his parents (Figs. 1a–2d). Here, DROP pipeline detected *PSMF1* mRNA aberrant splicing of most transcript (OUTRIDER, *PSMF1* as AE outlier, with fold change 0.13, z-score –9.84, FDR 6.29×10^{–14}; FRASER2, *PSMF1* as AS outlier, with |Δψ| 0.73, FDR 2.85×10^{–12}). Finally, in probands L-II-4 and M-II-6, fibroblasts RNA-seq revealed that the *PSMF1* splice variant c.764+5 G > A caused intron retention (Fig. 2d), and *PSMF1* was detected as significant splicing outlier in the two probands (FRASER2, *PSMF1* as AS outlier, with |Δψ| 0.88, FDR 4.06×10^{–5} in L-II-4 and with |Δψ| 0.89, FDR 9.05×10^{–6} in M-II-6; OUTRIDER, *PSMF1* not detected as AE outlier).

Splicing (minigene) assay. Minigene assay revealed that the *PSMF1* splice variant c.365+2 T > C (Pedigree R) led to intron retention (r.366_367inscacuucuaa) and premature termination (p.Thr123_Leu271-delinsHisPhe; Fig. 2e). Furthermore, the *PSMF1* splice variant c.605+1 G > A (Pedigree K) was proven to result in skipping of exon 5 (r.553_606del) and an in-frame deletion (p.Cys185_Gly202del; Fig. 2e).

To assess the potential functional impact of *PSMF1* splice variants in the substantia nigra, we analyzed *PSMF1* transcript expression using data from the GTEx database. This revealed that the transcript with the highest expression in the substantia nigra (ENST00000333082.7) shares an identical coding sequence –including the same ATG start codon and canonical splice sites– with the MANE Select transcript (NM_006814.5; ENST00000335877.11), differing only in untranslated regions. Consequently, disruptions of canonical splice sites affecting the MANE Select transcript are expected to similarly affect the substantia nigra isoform ENST00000333082.7. In fibroblasts, the most abundant *PSMF1* transcript (ENST00000479715.5) differs from the fibroblast-expressed isoform ENST00000333082.7 –which preserves the same coding sequence and canonical splice sites as the MANE Select transcript– only in a region corresponding to exon 2 and its flanking intronic sequences. This region includes the c.282+2 T > A and c.282+5 G > A variants, for which we demonstrated aberrant splicing in

transcripts from patient-derived fibroblasts (Fig. 2d). These findings demonstrate that the transcript isoform harboring the clinically relevant splice site is endogenously expressed in both fibroblasts and substantia nigra, supporting the pathogenic relevance of *PSMF1* splice-disrupting variants in a disease-relevant tissue.

Western blotting. Western blotting of protein lysate obtained from fibroblasts of probands L-II-4 and M-II-6 harboring the intron retaining *PSMF1* variant c.764+5 G > A in the homozygous state showed complete loss of anti-*PSMF1*/hPI31 antibody immunoreactivity (Fig. 2f). A severe reduction in anti-*PSMF1*/hPI31 immunoreactivity was also observed for probands A-II-2, F-II-3 and I-II-3 compared to their unaffected parents (A-I-1, A-I-2, F-I-1, F-I-2) and/or healthy controls (Fig. 2f). On the other hand, Western blotting of protein lysate from fibroblasts of proband B-II-3, who was homozygote for the *PSMF1* missense variant c.724 C > G p.(Arg242Gly) suggests that this variant does not impact protein stability and instead is most likely affecting protein function (Fig. 2f). Finally, Western blotting of protein lysate obtained from fibroblasts of proband O-II-5 (Fig. 1a), who was homozygote for the *PSMF1* start-loss variant c.1 A > T, revealed that *PSMF1*/hPI31 antibody immunoreactivity was abolished (Fig. 2g).

Proteomic analysis of human fibroblasts revealed alterations in proteasomal proteins and decreased levels of *PSMF1*/hPI31 in patients carrying homozygous splice variants

Differential expression analysis of the proteomes of *PSMF1* proband- and heterozygous carrier-derived fibroblasts was obtained by nano-liquid chromatography combined with mass spectrometry. This revealed statistically significant reduction in *PSMF1*/hPI31 in probands carrying homozygous *PSMF1* splice variants (J-II-3, L-II-4, M-II-6) compared to controls (Fig. 3a). Statistically significant reduction in *PSMF1*/hPI31 expression was also observed between probands harboring homozygous *PSMF1* splice variants and those with homozygous *PSMF1* missense mutations (B-II-3, F-II-3; Fig. 3b). On the contrary, *PSMF1*/hPI31 expression was not downregulated in probands carrying homozygous *PSMF1* missense variants compared to controls or carriers of a single heterozygous *PSMF1* missense variant (A-I-1, A-I-2, B-II-1, F-I-1, F-I-2; Fig. 3c–d). Interestingly, other proteasome-associated proteins were significantly upregulated in probands with homozygous *PSMF1* missense variants compared to homozygotes for *PSMF1* splice variants, heterozygotes for a *PSMF1* missense variants and controls (Fig. 3b–d), although the majority of these do not pass the log2 fold-change threshold of 1. Proteasome subunits B and proteasome activator complex subunits E were statistically significant in probands- and missense-homozygote




Fig. 3 | Quantitative proteomic analysis of PSMF1/hPI31 and proteasomal, mitochondrial/mitophagy and lysosomal proteins in PSMF1 patient- and carrier-derived primary dermal fibroblasts. Volcano plots showing: (a) statistically significant downregulation of PSMF1/hPI31 in affected individuals with homozygous *PSMF1* splice variants ($n = 3$; J-II-3, L-II-4, M-II-6) compared to healthy controls (HC); (b) Statistically significant reduction in PSMF1/hPI31 expression in affected individuals with homozygous *PSMF1* splice variants ($n = 3$; J-II-3, L-II-4, M-II-6) compared to probands with homozygous *PSMF1* missense variants ($n = 2$; B-II-3, F-II-3); (c) PSMF1/hPI31 expression was not downregulated in probands with homozygous *PSMF1* missense variants ($n = 2$; B-II-3, F-II-3) compared to HC or (d) unaffected individuals having a single heterozygous *PSMF1* missense variant ($n = 4$; A-I-1, B-II-1, F-I-1, F-I-2). Datapoints are colored within each quadrant of the volcano plot if their respective p-value and $\log_2$ fold-change pass the cut-offs ($0.05 > p$ OR

$p \leq 0.05$; y-axis; $FC > 1$ OR $FC \leq -1$; x-axis). These are further categorized according to their association with organelles (lysosome/mitochondria) or cellular processes (proteasome/mitophagy), as defined by the Curtain web tool: <https://curtain.proteo.info/#/>). Data were fit to a linear model and adjusted p-values computed using Benjamini-Hochberg false-discovery rate correction at 0.05. P-values < 0.05 are deemed statistically significant. Additional datapoints of interest relating to proteasomal and mitophagy proteins are annotated by text within each volcano plot. Groups: splice homozygotes ($n = 3$; J-II-3, L-II-4, M-II-6), missense homozygotes ($n = 2$; B-II-3, F-II-3), unaffected missense heterozygotes ($n = 4$; A-I-1, B-II-1, F-I-1, F-I-2), healthy controls (HC; $n = 2$; M:F = 0:1; age at skin biopsy (mean $\pm$ standard deviation) = 19.5 ± 0.5 years). Source data are accessible through links reported in Supplementary Notes 3.

mutations compared to heterozygous carriers and controls. Additional changes in abundance of mitophagy proteins, as well as proteins associated with the mitochondria and lysosome, are observed between patient groups (Fig. 3a-d). Further experiments, including undertaking organelle enrichment studies, are needed to comprehensively elucidate the mechanistic impacts of *PSMF1* missense and loss-of-function variants on protein abundance regarding proteasomal, mitochondrial and other implicated pathways.


Heterozygous rare and low-frequency *PSMF1* variants are not associated with increased risk of sporadic Parkinson's disease in the UKB and AMP-PD repositories

We looked for rare and low-frequency (minor allele frequency, $MAF < 0.005$) *PSMF1* variants in patients with sporadic (non-familial)

PD and controls in the UKB and AMP-PD repositories. Gene-burden analysis revealed that single heterozygous *PSMF1* variants do not contribute to the risk of developing sporadic PD (Supplementary Notes 2).

Real-time quaking-induced conversion assay did not identify misfolded α -synuclein seeding activity in three *PSMF1* probands

We performed α -synuclein (α -syn) Real-Time Quaking-Induced conversion (RT-QuIC) assay in the CSF of proband A-II-2 and in the skin of probands A-II-2, B-II-3 and I-II-3 according to an established protocol³⁹. All α -syn RT-QuIC runs with both matrices were negative (Supplementary Fig. 4), thus ruling out significant synucleinopathy as the substrate of nigrostriatal degeneration in these affected individuals.



PSMF1 variants can affect proteasomal abundance and assembly in human fibroblasts

Extensive evidence indicates that PI31 functions as a proteasome regulator and promotes proteolysis in multiple species, including *Drosophila*, mice, yeast, and plants^{18,21–23}. Furthermore, PI31 facilitates the recruitment of proteasomes at synaptic sites, and is essential for synapse maintenance and neuronal survival in *Drosophila* and mice^{20,21}. We preliminarily investigate the effects of *PSMF1* proband-derived fibroblasts. Native gel assays revealed a reduction in the amount of both 20S and 26S proteasome particles in samples from *PSMF1* probands A-II-2 and M-II-6 compared to healthy controls, as well as a reduction in the ratio of assembled 26S particles (Supplementary Fig. 5a). These observations are consistent with the previously

reported role of PI31 in promoting 26S assembly from 19S and 20S subparticles¹⁹. In addition, we detected reduced alpha-7 subunit immunoreactivity in F-II-3 proband-derived fibroblast samples, as assessed by both native gel and Western blot analysis. This is in keeping with reduced amounts of proteasomes in this *PSMF1* proband (Supplementary Fig. 5b).

PSMF1 variants are associated with mitochondrial dysfunction and alteration of mitochondrial dynamics and mitophagy in human fibroblasts

Mitochondrial dysfunction is well-recognized as a central and unifying feature of both genetic and idiopathic PD and parkinsonism^{40–42}. This dysfunction encompasses impaired mitochondrial electron transport chain (mETC) activity—particularly at complex I—disrupted cellular

Fig. 4 | PSMF1/hPI31 deficiency is associated with defects in mitochondrial bioenergetics and dynamics. (a–c) **Mitochondrial membrane potential status and maintenance:** (a) Representative images of tetramethylrhodamine methyl ester (TMRM)-loaded mitochondria in fibroblasts from healthy controls (HC1, HC2) and *PSMF1* probands (A-II-2, F-II-3; Fig. 1a). Scale bar = 20 μ m. (b) Quantification bar graphs depict the mean mitochondrial membrane potential for HC' (gray bars), probands' (orange bars) and unaffected carriers' (yellow boxes) mitochondria. Non-parametric Kruskal-Wallis ANOVA with post-hoc Dunn's test for each group. Data are presented as mean $\pm$ standard error of the mean (SEM). * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, ns = not statistically significant. (c) Inhibitor analysis of the mitochondrial membrane potential maintenance and electron transport chain function in HC (upper quadrants) compared to probands' (lower quadrants) mitochondria. (d) Representative NADH autofluorescence traces after application of 1 μ M FCCP and 100 mM NaCN in HCs (i) and in patients' fibroblasts (ii) and (iii); (e) Quantification bar chart depicting differences in redox indices in control and patient's fibroblasts from (d). Data are presented as mean $\pm$ SEM. Each dot represents an ROI and total number of cells (n) analyzed from 1–3 independent experiments (N) and is shown in brackets. Kruskal-Wallis test with Dunn's post hoc test was performed, *** $p < 0.001$. **Mitochondrial dynamics:** (f) Quantification box

charts depicting average length of all mitochondrial rod and branches and (g) average number of branches analyzed in individual fibroblasts from HC' (gray boxes), probands' (orange boxes) and unaffected carriers' (yellow boxes) fibroblasts. (h) Representative images of mitochondrial shape and dynamics in one unaffected carrier (B-II-1), one proband (B-II-3) and one HC (HC2). In (f) and (g) each dot represents a cell and total number of cells (n ; shown in brackets) analyzed in 3–9 independent experiments (N). Non-parametric Kruskal-Wallis ANOVA with post-hoc Dunn's test for each group. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ compared to control HC1; # $p < 0.05$, ## $p < 0.01$, ### $p < 0.001$ compared to control HC2. Scale bar = 20 μ m. **Mitophagy:** (i) Basal mitophagy rate assessed as co-localization of LysoTracker Red DND-99 with MitoTracker Green in HC (gray bars), probands' (orange bars) and unaffected carriers' (yellow bars) fibroblasts. (j) Mitophagy rate after induction with either lactate or pyruvate. In (i) and (j) each dot represents the number of cover slips (n ; shown in brackets) from 3–6 independent culturing conditions (N). Non-parametric Kruskal-Wallis ANOVA with post-hoc Dunn's test for each group. Data are presented as mean $\pm$ SEM. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, ns = not statistically significant. In all panels, blue denotes increased statistical significance, and red denotes decreased significance. Source data are provided as a Source Data file.


bioenergetics, elevated oxidative stress, and failure of mitochondrial quality-control pathways, including mitophagy^{41,42}. Notably, mitochondrial pathology has been observed in *FBXO7*-related disorder^{27,43,44}. In particular, a human fibroblast line carrying a missense variant in *FBXO7* causes ablation of the *PSMF1*/hPI31-*FBXO7* interaction, leading to proteasomal and mitochondrial dysfunction²⁶. Based on extensive evidence of mitochondrial dysfunction in neurodegenerative disorders, including *FBXO7*-related disease, we explored the effects of *PSMF1* variants on mitochondrial function and mitophagy using live imaging of skin fibroblast from *PSMF1* probands and carriers.

Mitochondrial membrane potential. Most processes in mitochondria depend on the mitochondrial membrane potential (MMP), whose detection in live cells is an important indicator of healthy mitochondrial functioning. Using tetramethylrhodamine methyl ester (TMRM) as fluorescent probe for MMP, we found that TMRM fluorescence in fibroblasts from *PSMF1* probands was similar or higher and in unaffected *PSMF1* carriers even higher than in controls (Fig. 4a, b), which suggests mitochondrial hyperpolarization. Since MMP is mainly maintained by the function of the mETC, any perturbation of mitochondrial respiration switches mETC to alternative mechanisms to maintain MMP in the physiological range, including reversal of the activity of the F₀-F₁-ATPase (complex V). Fibroblasts from controls or *PSMF1* carriers showed no effect or small increase in TMRM fluorescence after application of the mitochondrial complex V inhibitor oligomycin (2 μ g/ml; Fig. 4c, upper quadrants), indicating that that enzyme is working as ATP synthase. On the contrary, addition of oligomycin to *PSMF1* proband-derived fibroblasts induced >50% depolarization (Fig. 4c, lower quadrants), which suggests that complex V is working in ATPase mode due to pathological mETC functioning in these cells. Subsequent application of the inhibitor of mitochondrial complex I rotenone (5 μ M) induced decrease in TMRM fluorescence in control (by ~50%) or *PSMF1* carriers' fibroblasts (by ~60%; Fig. 4c, upper quadrants), whereas in *PSMF1* probands' cells it induced complete mitochondrial depolarization, seen by the lack of effect of the mitochondrial uncoupler carbonyl cyanide p-trifluoromethoxyphenylhydrazone (FCCP; 1 μ M) on TMRM fluorescence after oligomycin and rotenone in these fibroblasts (Fig. 4c, lower quadrants). In control or *PSMF1* carriers' fibroblasts, subsequent application of FCCP induced further drop of the TMRM signal (by 30–40%) to a complete depolarization (Fig. 4c, upper quadrants). Overall, control fibroblasts maintain MMP solely by the function of the mETC (including complexes I and II), while MMP maintenance (~50%) in probands' fibroblasts depends on ATP

consumption by the F₀-F₁-ATPase and the activity of complex I. Relevantly, we previously observed similar changes in MMP maintenance in other cells with PD pathology, including *PINK1*-deficient cells, neurons with *SNCA* triplication and neurons with mitochondrial DNA variants^{45–47}. We observed variability in TMRM fluorescence that may reflect several contributing factors, including the absence of multiple affected siblings from the same pedigree (i.e., individuals of similar age within the same generation), age differences between affected participants and their clinically unaffected parents, and the possibility that clinically unaffected heterozygous carriers exhibit subclinical mitochondrial dysfunction associated with a heterozygous *PSMF1* variant.

Mitochondrial respiration. Higher MMP observed in fibroblast from *PSMF1* probands and carriers, together with changes in the mechanisms that maintain MMP (Fig. 4b, c), suggest altered mitochondrial respiratory activity which is compensated by alteration in the ATP synthase activity. NADH serves as the substrate and electron donor for mitochondrial complex I, and assessing the balance between NADH production in the tricarboxylic acid cycle and its consumption by complex I (redox index) can provide insight into mitochondrial functional status⁴⁸. Application of the mitochondrial uncoupler FCCP (1 μ M) activates mitochondrial respiration and depletes mitochondrial NADH (defined as 0%; Fig. 4d), whereas subsequent addition of NaCN (1 mM) inhibits mitochondrial respiration and blocks NADH oxidation by complex I (defined as 100%). Using this assay, we found that the redox index in the fibroblasts from two *PSMF1* probands was lower than in those from healthy controls, which suggests accelerated NADH consumption and possible mitochondrial uncoupling (Fig. 4e). Taken together, these findings suggest that *PSMF1* variants promote mitochondrial uncoupling, leading to a reversal of the F₀-F₁-ATPase and ATP consumption—rather than ATP synthesis—to compensate for complex I dysfunction and loss of MMP.

Mitochondrial dynamics. Mitochondrial dynamics are essential for proper mitochondrial metabolism and function. Mitochondria in *PSMF1* proband- and control-derived fibroblasts differ not only by the TMRM signal intensity but also by their shape and size (Fig. 4f–h). Further analysis of the mitochondrial shape showed that mitochondria in the probands' fibroblasts appeared more fragmented and have shorter mitochondrial branch length (Fig. 4f) and lower mean number of branches per network (Fig. 4g) than control fibroblasts. Interestingly, fibroblasts of *PSMF1* carriers had even longer mitochondrial branch length and mean number of branches per network than in control and probands' fibroblasts (Fig. 4f–h). Therefore, *PSMF1*



variants are associated with changes in mitochondrial dynamics, which could be secondary to an alteration of fission/fusion mechanisms or mitophagy.

Mitophagy. Damaged or depolarized mitochondria are engulfed by lysosomes during mitophagy. To detect this translocation by live imaging of participant-derived fibroblasts, we analyzed the co-

localization of mitochondria loaded with the green-fluorescent dye MitoTracker® Green FM with lysosomes loaded with the red-fluorescent dye LysoTracker Red DND-99⁴⁹. Although basal mitophagy levels in fibroblasts are relatively low and the difference between PD and control cells is difficult to detect⁵⁰, we found that the percentage of co-localization in *PSMF1* probands' fibroblasts was lower than in *PSMF1* carriers (Fig. 4i). Mitophagy activation by 30 mM lactate

Fig. 5 | Effects of pan-neuronal *PI3I* knockdown in *Drosophila*. (a) Setup for comparative climbing test of three different *Drosophila* RNA interference (RNAi) lines (*nsmase*, *prkn*, *PI3I*) with *prkn* used as positive control (significant motor impairment) and *nsmase* as a negative control (no motor impairment). *H. sapiens* and *Drosophila* orthologues: *PRKN* (*H. sapiens*)/*prkn* (*Drosophila*); *PSMF1* (*H. sapiens*)/*PI3I* (*Drosophila*); *SMPD2* (*H. sapiens*)/*nsmase* (*Drosophila*). **b** Climbing test performed at Days 10, 20 and 35 after eclosion represented as percentage of flies that did not reach the 5-cm tube threshold ($N = 3$, $n \geq 15$). Significant motor defect was observed at Day 35 after eclosion for the *PI3I* ($p = 0.0078$) and *prkn* ($p = 0.0091$) lines compared to the negative control *nsmase*. Analyses are two-tailed Fisher's exact tests. **c** Whole-brain mitochondrial membrane potential. **c-i** Representative images of TMRM fluorescence in whole brain preparations from 35 days post-eclosion *PI3I*- and control *nsmase*-knockdown flies (scale bar = 50 μ M). **c-ii** Quantification of mean TMRM fluorescence within region of interests (ROIs) encompassing the whole central brain. N values are number of brains. Error bars are standard error of the mean (SEM). Analysis is two-tailed Mann-Whitney U-test. *** $p = 0.0008$. **d-i** Schematic showing the location of dopaminergic neuron clusters

in the adult *Drosophila* brain: PPM1-3, protocerebral posterior medial clusters 1–3; PPL1-2c, protocerebral posterior lateral clusters 1–2c. Created in BioRender. Jepson, J. (2026) <https://BioRender.com/go7p1bj>. **d-ii** Representative image of anti-TH immunostaining in a control (*nsmase*-knockdown, 5 days after eclosion) brain, with the same neuronal clusters indicated (scale bar = 50 μ M). Total number of TH+ cell bodies in young (5–7 days after eclosion) (**e-i**) and aged (40 ± 5 days after eclosion) (**f-i**) brains. N values are number of brains. Analysis is two-tailed unpaired t -test. $p = 0.0034$. **e-ii**, **f-ii** Representative images of anti-TH immunostaining in the indicated genotype (scale bar = 50 μ M), with enlarged sections showing PPM3 clusters (scale bar = 20 μ M). **e-iii**, **f-iii** Number of TH+ cell bodies in indicated clusters per hemisphere (i.e. two data points per brain). Indicated n values are the number of brains. Error bars are SEM. Analyses are two-tailed Mann-Whitney tests within clusters, with False Discovery Rate correction for multiple comparisons. q values for **e-iii** = 0.766, 0.159, 0.396 and 0.159 for PPM1 + 2, PPL1 + 2c, PPM3 and PPL2ab, respectively. q values for (**f-iii**) = 0.446, 0.071, *0.034, and 0.152, respectively. Source data are provided as a Source Data file.

or 30 mM pyruvate⁵⁰ increased the percentage of mitochondria-lysosome co-localization in all fibroblasts, but to a higher extent in control and *PSMF1* carriers' fibroblasts than in probands' fibroblasts (Fig. 4j).

***PI3I* knockdown in *Drosophila* causes age-dependent locomotor dysfunction, dopaminergic neurodegeneration, and mitochondrial membrane depolarization**

We utilized the UAS/Gal4 system⁵¹ to induce pan-neuronal (*nSyb-Gal4*) RNA interference (RNAi)-mediated knockdown of *PI3I* in *Drosophila*. We similarly generated positive (knockdown of the established PD-related gene *prkn*) and negative (knockdown of *nsmase*, previously used as a negative control)⁵² controls.

Behavioral analysis (negative geotaxis climbing assay). Motor performance of *PI3I*-knockdown flies was assessed using the classic negative geotaxis climbing assay (Fig. 5a, b). We observed no difference in climbing performance between the three groups at 10 or 20 days after eclosion, but at 35 days both *prkn*- and *PI3I*-knockdown flies exhibited impaired motor performance in the form of a significantly reduced proportion of flies climbing past a 5-cm threshold relative to a previously established *nsmase* negative control (*nsmase* vs *prkn*, $p = 0.0091$; *nsmase* vs *PI3I*, $p = 0.0078$; Fig. 5b). These observations are consistent with loss of PI3I function causing motor dysfunction in aged flies to a degree comparable to established *Drosophila* PD models^{53,54}.

Mitochondrial membrane potential. Since we observed mitochondrial membrane depolarization in fibroblasts derived from *PSMF1* probands in response to complex I and V inhibitors, we used the *Drosophila* model to explore whether this occurred under normal physiological conditions in the context of an organismal model. At 35 days after eclosion, the stage at which motor defects became apparent, we observed a brain-wide decrease in TMRM fluorescence in *PI3I*-knockdown flies relative to *nsmase* negative controls, again comparable to reports in established *Drosophila* PD models (Fig. 5c)⁵⁵. These data indicate a highly conserved function of *PSMF1*/hPI3I and PI3I between *D. melanogaster* and *H. sapiens*, and are consistent with loss of PI3I function leading to mitochondrial dysfunction and depolarization.

Brain immunohistochemistry. Loss of *prkn* function in *Drosophila* causes progressive degeneration of dopaminergic neurons⁵⁶. We therefore tested whether this hallmark of PD was apparent in *PI3I*-knockdown flies. The location of dopaminergic neuron clusters in the *Drosophila* brain is well characterized, and they are readily visualized via immunostaining against tyrosine hydroxylase (TH) (Fig. 5d). In


young (5–7 days post-eclosion) flies there was no difference in the total number of TH+ cell bodies between *PI3I*- (mean $\pm$ SEM: 31.31 ± 1.06) and *nsmase*-knockdown (29.29 ± 0.946) brains ($p = 0.170$) (Fig. 5e-i), or in the number of neurons within individual clusters (Fig. 5e-ii, 5e-iii). However, we counted significantly fewer TH+ cell bodies in aged (40 ± 5 days post-eclosion) *PI3I*-knockdown (26.19 ± 0.965) brains relative to *nsmase* negative controls (29.67 ± 0.6701) ($p = 0.0034$) (Fig. 5f-i), with significantly reduced numbers in the PPM3 cluster and a trend towards reduction in the PPL1 + 2c clusters ($q = 0.071$) (Fig. 5e-ii, 5e-iii). This is consistent with loss of PI3I function causing PD-like progressive degeneration of dopaminergic neurons in *Drosophila*.

Conditional inactivation of *Psmf1* in mice leads to motor dysfunction and diffuse gliosis

Mouse PI3I protein is 83% identical and 91% similar to human *PSMF1*/hPI3I. Members of our team previously reported that *Psmf1* inactivation in mouse neurons causes age-progressive neurological phenotypes which culminate in neuronal cell death²¹. To better examine the consequences of impaired PI3I function in the mouse, we bred mice with a tamoxifen-inducible Cre recombinase system with a Cre-ERT2 fusion gene under the control of the human ubiquitin C promoter (UBC-Cre-ERT2)⁵⁷ with mice containing a loxP-flanked (floxed) third exon of *Psmf1* (*Psmf1*^{fl})²¹, thus obtaining conditional knockout (CKO) of *Psmf1*. This strain enables conditional inactivation of *Psmf1* upon tamoxifen injection. To assess recombination efficiency, these mice also carried a transgenic Cre reporter, Ai14⁵⁸, which has a floxed STOP cassette preventing transcription of a CAG promoter-driven red fluorescent protein variant (tdTomato) inserted into the Gt(Rosa)26Sor locus. Upon successful Cre-mediated recombination, Ai14 mouse tissues express tdTomato red fluorescence. Depending on the amount of tamoxifen injected, we obtained recombination efficiency ranging from 30% to over 90% (Fig. 6a, b and Supplementary Fig. 6).

Behavioral tests

Rotarod assay. We first assessed motor performances of *Psmf1* CKO mice using the rotarod test (Fig. 6c, d). *Psmf1*^{fl/fl} Ai14 UBC-Cre-ERT2 mice were injected with tamoxifen or corn oil as control at 6–7 weeks of age, while *Psmf1*^{fl/fl} Ai14 mice without Cre were injected with tamoxifen as an additional control for tamoxifen. Ten days after the last injection, mice were trained for four days on the rotarod and then tested once on each day after for 11 days (Fig. 6c, d) and thrice on the subsequent day. Initially the performance of tamoxifen-injected *Psmf1*^{fl/fl} Ai14 UBC-Cre-ERT2 mice with a high recombination rate (> 90% of neurons as assessed by Ai14) displayed a deficit by day 12, whereas tamoxifen-injected *Psmf1*^{fl/fl} Ai14 UBC-Cre-ERT2 mice with a



low recombination rate (approximately 30% of neurons as assessed by Ai14) showed only a mild deficit (Fig. 6c, d).

Open field assay. Since individuals with *PSMF1*-related PD or parkinsonism present with severe anxiety, we also tested *Psmf1^{fl/fl}* Ai14 UBC-Cre-ERT2 mice in the open field assay with dark insert. Anxiety-like behavior of rodents is frequently accompanied by reduced

exploration. On day 26 after tamoxifen injection, *Psmf1^{fl/fl}* Ai14 UBC-Cre-ERT2 mice displayed a clear difference to controls, consistent with increased anxiety (Fig. 6e).

Brain immunohistochemistry. We observed gliosis in various brain regions 28 days after tamoxifen injection in *Psmf1^{fl/fl}* Ai14 UBC-Cre-ERT2 mice. Many neurodegenerative diseases are associated with

Fig. 6 | Behavioral tests and neuropathology in mice with conditional *Psmf1* inactivation. **a** *Psmf1^{fl/mi}* UBC-Cre-ERT2/+ Ai14/+ brains post perfusion (28 days after injection of tamoxifen or corn oil as a control). Tamoxifen-induced recombination induced tdTomato (red) expression and marked cells in which *Psmf1* was inactivated (Supplementary Fig. 6). Successful tamoxifen-induced recombination was macroscopically assessed based on the color of dissected mouse brains, which appeared dark pink in mice with severe motor deficit in the rotarod assay (m6, m9) and light pink in mice with mild to no motor deficit in the rotarod assay (m1, m5) compared to controls (ctrl1, ctrl2), which reflected high (~90%) or low (30–50%) recombination rates, respectively. *Psmf1^{fl/mi}* Ai14 UBC-Cre-ERT2 mice were injected with either corn oil (control) or tamoxifen to induce Cre recombination of floxed *Psmf1* exon 3 for loss of *Psmf1* and a floxed stop cassette in Ai14 for expression of tdTomato to evaluate recombination efficiency. Mice were sacrificed 28 days post injection. **b** Quantification of PI31 protein levels in mice. Western blot analysis for PI31 and Gapdh of whole brain extracts from mice 20 days post tamoxifen injection for high recombination rate. Less than 6% PI31 remains in tamoxifen-injected Cre mice. Quantification of Western blots by densitometry, $n = 4$ *Psmf1^{fl/mi}*, $n = 3$ *Psmf1^{fl/mi}* UBC-Cre-ERT2. Error bars indicate standard deviations. Two-tailed unpaired T-test, **** $p < 0.0001$. **c–d** Rotarod assay. In the rotarod assay, mice with high recombination rates (~90%) developed severe motor deficits (light blue line in (c) and light blue bar in (d)), whereas the motor performance of mice with low (30–50%) recombination rates was mildly or not impaired (green line in (c) and green bar in (d)). **c** Shows single rotarod trials for individual mice on each day. X-axis indicates days of testing after the initial four-day training period. Day 1 corresponds to Day 14 after tamoxifen injection. In (d), each bar represents the average of three trials for a mouse on Day 25 post tamoxifen injection (i.e., 12 days after the initial four-day training period). Error bars indicate standard deviations. One-way ANOVA with

Tukey post-hoc test. $n = 6$ *Psmf1^{fl/mi}* Ai14/+ corn oil, $n = 6$ *Psmf1^{fl/mi}* Ai14/+ tamoxifen, $n = 12$ *Psmf1^{fl/mi}* Ai14/+ UBC-Cre-ERT2/+ corn oil, $n = 6$ *Psmf1^{fl/mi}* Ai14/+ UBC-Cre-ERT2/+ tamoxifen low recombination rate, and $n = 8$ *Psmf1^{fl/mi}* Ai14/+ UBC-Cre-ERT2/+ tamoxifen high recombination rate. ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$. **e** Dark/light open field assay. Mice with high recombination rates (~90%, fourth subgroup) strongly avoided walking in the open field, which reflects severe anxiety-related behavior. In contrast, the motor performance of mice with low recombination rates (30–50%, third subgroup) was comparable to controls. Error bars indicate standard deviations. One-way ANOVA with Tukey post-hoc test. $n = 24$ *Psmf1^{fl/mi}* Ai14/+ tamoxifen, $n = 6$ *Psmf1^{fl/mi}* Ai14/+ UBC-Cre-ERT2/+ tamoxifen low recombination rate, and $n = 5$ *Psmf1^{fl/mi}* Ai14/+ UBC-Cre-ERT2/+ tamoxifen high recombination rate. * $p < 0.1$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$. **f** Sagittal brain sections stained with either Iba1 (green) for microglia or GFAP for glia (astrocytes) and with Hoechst 33342 for nuclei (blue). TdTomato (red) fluorescence indicates recombination efficiency. **(i)** In the deep cerebellar nuclei (DCN), reactive microglia in tamoxifen-induced mice indicated gliosis induction. Scale bar = 100 μ m. **(ii)** Higher magnification in the DCN shows morphologically distinct ramified microglia with more amoeboid appearance upon loss of *Psmf1*. Scale bar = 20 μ m. **(iii)** In the DCN of tamoxifen-induced mice, we observe an increase in glia staining strongly for GFAP in the DCN, a marker for astrogliosis (of note, GFAP also stains the Bergmann glia in the molecular layer). Scale bar = 100 μ m. **(iv)** Higher magnification image of **(iii)**. Scale bar = 20 μ m. **g** Quantification of percent area positive for signal of either GFAP or Iba1 staining in the DCN. Error bars indicate standard deviations. Two-tailed unpaired T-test, $n = 3$ *Psmf1^{fl/mi}* Ai14/+ UBC-Cre-ERT2/+ corn oil and $n = 3$ *Psmf1^{fl/mi}* Ai14/+ UBC-Cre-ERT2/+ tamoxifen. * $p < 0.05$, *** $p < 0.001$. Source data are provided as a Source Data file.

gliosis, where glial cells become reactive and proliferate generally prior to the formation of aggregates, tangles and plaques, including PD^{59–63}. Significantly, we detected both microgliosis, as documented by increased staining of microglia with anti-Iba1 and a change in morphology of the microglia from ramified to more amoeboid, and astrogliosis, as demonstrated by elevated GFAP-staining of astrocytes (Fig. 6f–g; Supplementary Figs. 7–8).

Discussion

Here we have provided extensive phenotypic, genetic and functional evidence to establish *PSMF1* as a human disease gene implicated in parkinsonism, childhood neurodegeneration, and perinatal lethality. Specifically, we reported 18 pedigrees in which biallelic *PSMF1* missense and loss-of-function variants co-segregated with a clinical spectrum ranging from early-onset PD resembling well-established recessive monogenic forms (e.g. *PRKN*, *PINK1*, *DJ-1*, *FBXO7*) to perinatal lethality with neurological manifestations. Notably, we observed a clear genotype-phenotype correlation. Individuals carrying *PSMF1* missense variants had normal neurodevelopmental milestones and manifested with parkinsonism between the first and fifth decade of life. Their clinical picture often encompassed mild pyramidal tract involvement, early dysphagia and psychiatric manifestations, and severely abnormal presynaptic dopaminergic imaging was consistent with nigro-striatal degeneration. These individuals showed various response to antiparkinsonian therapies and developed early motor and non-motor fluctuations and dyskinesia. Notably, the observation of preserved ¹²³I-MIBG myocardial uptake and negative α -syn RT-QuIC assays in individuals with *PSMF1*-related PD/parkinsonism parallels the biomarker pattern observed in other early-onset monogenic forms of PD, such as those associated with variants in *PRKN* and *PINK1*^{64–67}. This observation supports the hypothesis that *PSMF1*-related PD/parkinsonism may result from alternative molecular pathways that do not (primarily) involve α -synuclein aggregation. Although we did not observe an enrichment of rare coding and splice variants in *PSMF1* among non-familial PD cases compared to controls in the UKB and AMP-PD datasets, further screening of large-scale PD repositories - including familial cases and regulatory variants - is necessary to better establish the frequency of this disorder and the potential contribution

of heterozygous *PSMF1* variants to PD risk. Moving forward into the disease spectrum, patients harboring biallelic *PSMF1* splice variants exhibited parkinsonism and/or other movement disorders and neurological manifestations since childhood or adolescence. Most often, these occurred in the context of neurodevelopmental delay and showed rapid progression leading to death within the second decade. Finally, subjects with two *PSMF1* loss-of-function variants, of which at least one was predicted to abolish *PSMF1* expression, presented with neurological manifestations and structural brain abnormalities since the prenatal period and died within infancy. Intriguingly, *PSMF1* loss-of-function variants were almost invariably associated with agenesis or hypoplasia of the corpus callosum, which consists of millions of axons connecting the cerebral hemispheres. Since PI31 has been demonstrated to mediate neurosome-to-synapse fast transport and be crucial for synapse maintenance and neuronal survival in *Drosophila* and mice^{20,21}, it is tempting to speculate that loss of *PSMF1*/hPI31 in humans affects axonal pathways leading to failed axonogenesis/synaptogenesis or premature degeneration of these neural structures, which would fuel the notion of altered neurodevelopment as primer of neurodegeneration.

PSMF1 encodes the evolutionarily highly conserved proteasome regulator *PSMF1*/hPI31, which is ubiquitously expressed in human tissues, including the brain. *PSMF1* shows strong protein expression in fetal brain tissue compared to non-brain tissues and elevated gene expression during the prenatal period across all brain regions⁶⁸. This could explain the widespread brain effects of its deficiency, not limited to the dopaminergic system. Notably, deep phenotyping of our study cohort revealed a tendency towards obesity and glucose intolerance, early osteoporosis/osteopenia and severe infections. Further delineation of *PSMF1*-related disorder will clarify whether *PSMF1*/hPI31 deficiency might have multisystemic involvement in humans.

Our findings suggest that different *PSMF1* mutant alleles drive disease via multiple loss-of-function mechanisms. In particular, the three missense variants p.Arg242Gly, p.Arg242Cys and p.Arg242His detected in six pedigrees with early-onset PD or parkinsonism affect a highly conserved residue within the natively disordered proline-rich C terminal of *PSMF1*/hPI31. In vitro characterization of the complex human *PSMF1*/hPI31-bovine 20S proteasome has demonstrated that

PSMF1/hPI31 Arg242 is inserted into the proteasome catalytic site, which results in an inhibitory mechanism⁶⁹. Considering the evidence of PI31 acting as a 20S proteasome inhibitor and a 26S proteasome upregulator in vitro as well as a proteasome enhancer in vivo, further studies are needed to establish whether variants at the Arg242 residue determine loss of function by converting PSMF1/hPI31 from a proteasome inhibitor to a proteasome substrate, or by disrupting proteasome positive regulation, thus supporting the role of proteasome inhibition in the pathogenesis of PD. Similarly, the missense variant p.Leu53Met, identified in two consanguineous families descended from a distant common ancestor, is located at the dimerization interface of PSMF1/hPI31 and is likely to disrupt hydrophobic interactions within the PSMF1/hPI31 homodimer, possibly influencing its activity on the proteasome and the stability of the PSMF1/hPI31-FBXO7 heterocomplex. Finally, *PSMF1* predicted and proven loss-of-function variants in our cohort are associated with moderate-to-severe phenotypes within the reported spectrum. We acknowledge that the lack of biological material beyond DNA from probands E-II-4 and H-II-1 precluded functional validation of the pathogenicity of their private *PSMF1* missense variants, c.725 G > A p.(Arg242His) and c.682 C > G p.(Leu228-Val). Additionally, further analysis is needed to establish why biallelic *PSMF1* splice variants lead to a milder, non-perinatal lethal phenotype compared to *PSMF1* putative or confirmed complete loss-of-function variants, particularly for those splice variants without evidence of alternative splicing from RNA-seq data.

PI31 is a high-affinity binding partner to FBXO7 in *Drosophila* and mammalian cells.^{26,27} Phenotypic features of *PSMF1* patients are reminiscent of those of *FBXO7*-related disorder, such as a clinical spectrum including juvenile-onset PD/parkinsonism, pyramidal tract signs only, or a combination thereof, initial response to levodopa and early occurrence of levodopa-induced dyskinesia²⁴. Human neuropathology is not available for *PSMF1*- and *FBXO7*-related disorders, but dopaminergic imaging indicates dramatic reduction in the nigrostriatal dopaminergic innervation in both disorders²⁴. None of the *PSMF1* variants identified in our cohort is predicted to affect amino acid residues at the interface between PSMF1/hPI31 and FBXO7. Therefore, it remains elusive whether PSMF1/hPI31 deficiency induces PD/parkinsonism per se, or by secondary disruption of FBXO7 functions in humans. Recently, ablation of the FBXO7-PSMF1/hPI31 interaction by an *FBXO7* missense variant has been demonstrated to affect expression and stabilization of these proteins as well as proteasomal and mitochondrial pathways in human fibroblasts²⁶. Importantly, *Fbxo7/ntc* variants cause site-specific proteolytic cleavage and reduced PI31 activity in *Drosophila* and mice^{18,26,27}. Moreover, transgenic PI31 overexpression in *Fbxo7*-null *Drosophila* and mice can robustly suppress neurological defects⁷⁰. This suggests that loss of *Fbxo7* causes disease to a considerable extent by attenuating PI31 functions. Since FBXO7 acts synergically with PINK1 and PRKN to regulate basal mitochondrial functions and stress-induced mitophagy^{44,71}, we explored mitochondrial pathways by live imaging of *PSMF1* patient-derived fibroblasts and documented mitochondrial dysfunction and alteration of mitochondrial dynamics and mitophagy. Additionally, we provided preliminary evidence that *PSMF1* variants may affect proteasomal abundance and assembly in human fibroblasts. Further studies are needed to fully characterize the consequences of *PSMF1* variants on mitochondrial homeostasis and, most importantly, to delineate their effects on proteasomal functions, whose disruption is likely to be the primary pathomechanism driving *PSMF1*-related pathology.

Besides documenting a similar age-dependent locomotor dysfunction in *PI31*- and *prkn*-knockdown *Drosophila*, our study demonstrates that *PI31* deficiency leads to progressive dopaminergic neurodegeneration, accompanied by brain-wide mitochondrial membrane depolarization in old flies, thus paralleling observations in other *Drosophila* PD models and mitochondrial dysfunctions observed in *PSMF1* human fibroblasts. Comparison between *Psmf1* knockout

mouse models (previous data and current study) and humans with *PSMF1*-related disorder reveals striking parallelism. Similarly to *Psmf1*-null mice, which die at advanced embryonic stages²¹, humans with biallelic complete or putative severe loss-of-function *PSMF1* variants (Pedigrees N-O-P-Q-R) exhibited severe neurological manifestations and structural brain abnormalities since prenatal development and died within infancy. On the contrary, conditional *Psmf1* knockout mice develop age-dependent motor dysfunction²¹, which is in keeping with motor phenotypes and the survival into adolescence or adulthood of patients harboring biallelic *PSMF1* splice and missense variants which are predicted to cause partial loss of function. Brain autopsy of our mouse model revealed diffuse micro- and astrogliosis with ameboid microglia, which likely reflects early neurodegeneration stages and the timing at which mice were sacrificed before neuropathology could be more informative. Further studies are needed, including expression of hypomorphic and knockin *Psmf1* variants in mice, to provide detailed insights into dopamine neurochemical changes, response to levodopa, and the neuropathology of *PSMF1*-related disorder.

In conclusion, this study establishes a causal relationship between biallelic *PSMF1* variants and early-onset PD, parkinsonism and neurodegeneration as well as perinatal lethality in humans. Our data reveal impairment of proteasomal abundance and assembly as well as mitochondrial membrane potential, respiration, dynamics and mitophagy in *PSMF1* patient-derived fibroblasts, preliminarily suggesting disruption of proteasomal and mitochondrial pathways as contributing pathomechanisms in PSMF1/hPI31 deficiency. Additionally, we demonstrate that inactivation of *PI31* in *Drosophila* and of *Psmf1* in mouse leads to age-dependent motor dysfunction, with wide-brain mitochondrial membrane depolarization and loss of dopaminergic neurons in aged flies as well as diffuse gliosis in mice. Evidence presented herein, along with previous literature, suggests that PSMF1/hPI31 is implicated in converging pathways of human neurodegeneration. In support of this, recent findings demonstrate that transgenic PI31 overexpression can robustly suppress phenotypes of *Fbxo7*-knockout *Drosophila* and mice⁷⁰. Collectively, our study—considered alongside these complementary observations—underscores the need to elucidate the role of PSMF1/hPI31 in human neurobiology and raises the possibility that it may serve as a target for future disease-modifying treatment approaches in human neurodegenerative disorders.

Methods

Written informed consent for diagnostic and research activities, as well as for publication of anonymized clinical information, radiological images, and genetic results, was obtained from all study participants or their parents/guardians. Research involving human participants and derivatives was conducted in accordance with the study protocol “International Genetics Collaboration (IGC)”, approved by the Health Research Authority and Health and Care Research Wales (IRAS project ID: 310045), and in compliance with the Declaration of Helsinki. Participants in this study were not provided with any monetary compensation for their involvement, other than reimbursement for travel expenses incurred to attend the study centers. All experiments involving *D. melanogaster* were performed following established institutional and international best practices for invertebrate research. As *Drosophila* is not regulated under animal experimentation legislation in France and the United Kingdom, formal ethical approval was not required. Flies were maintained under standard conditions, and all procedures were designed to minimize stress and unnecessary harm. All experiments involving *M. musculus* were performed in the United States in accordance with the United States Animal Welfare Act and the National Institutes of Health (NIH) policies to ensure proper care and use of laboratory animals for research, according to established guidelines and under the supervision of the Institutional Animal Care and Use Committee (IACUC) of The Rockefeller University. The study protocol (#23016)

was approved by Dr. Engin Ozertugrul, PhD, M.Ed. Mice were housed in accredited facilities of the Association for Assessment and Accreditation of Laboratory Animal Care (AALAC) in accordance with NIH guidelines. Housing conditions of *M. musculus* were as follows: dark/light cycle 12 h/12 h, temperature range 68–79 °F, and relative humidity range 30–70%.

Patient recruitment, phenotypic assessment, sampling and primary dermal fibroblast culture

Clinical and prenatal ultrasound assessments were conducted by experienced pediatric and adult neurologists and obstetrician-gynecologists, respectively. A detailed clinical proforma was completed by recruiting clinicians and clinical geneticists of affected individuals. Videos of the neurological assessment were critically reviewed by experienced neurologists with expertise in movement disorders (Fr. Ma., Ka. P. Bh.). Neuroimaging was reviewed by an experienced pediatric neuroradiologist (Ma. Se.). Genomic DNA was extracted from whole blood or amniotic fluid cells (proband R-II-2), and RNA was extracted from whole blood (parents J-I-1, J-I-2) according to standard procedures and protocols. In proband J-II-3, a muscle biopsy from the left anterior thigh was performed according to standard procedures and protocols. Punch skin biopsies of proband A-II-2 and his unaffected parents (A-I-1, A-I-2), proband B-II-3 and her unaffected brother (B-I-1), proband F-II-3 and his unaffected parents (F-I-1, F-I-2) and probands J-II-3, L-II-4 and M-II-6 (Fig. 1a) were collected according to standard procedures and protocols for primary dermal fibroblast culture for RNA and protein lysate extraction as well as for live cell imaging experiments. A punch skin biopsy was obtained from proband P-II-5 for primary dermal fibroblast culture to extract protein lysate and perform Western blotting. Punch skin biopsies of individuals B-II-1 and I-II-3 were obtained at a later stage of the study and used for primary dermal fibroblast culture to extract protein lysate and perform Western blotting and proteasome assays. Human primary dermal fibroblasts, SH-SY5Y cells (female donor), and HepG2 cells (male donor) were cultured in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% v/v fetal bovine serum (FBS) and maintained in a humidified tissue culture incubator at 37 °C, 5%/95% CO₂/air mixture. To generate *PSMF1* knockdown SH-SY5Y, 1×10^6 cells were reverse transfected with 100 nM small interfering RNA (siRNA) smartpools (non-targeting, Dharmacon D-001206-13-05; *PSMF1* targeting, Dharmacon M-012320-01-0005) in 6-well plate format using 0.3% v/v DharmaFECT1 (Dharmacon T-2001-01). All fibroblast lines derived from *PSMF1* affected individuals and unaffected family members were genotyped via Sanger sequencing before each set of experiments (RNA extraction, protein extraction, RT-QulC, proteasome assays, and live cell imaging for mitochondrial studies). To perform α -syn RT-QulC analysis, in probands A-II-2, B-II-3 and I-II-3, 3-mm skin punch biopsies were obtained unilaterally, after intradermal anesthesia, from the dorsal cervical region at the C7–C8 dermatomes and from the distal leg 10 cm proximally to the lateral malleolus, according to guidelines⁷². Skin samples were immediately frozen in dry ice. In proband A-II-2, on the same day of skin biopsy, a lumbar puncture was performed at the L3–L4 level, according to guidelines^{39,73}. CSF was collected in 5 ml polypropylene tubes (Sarstedt, code number 63.504.027), centrifuged at $1000 \times g$ for 10 min at room temperature, and divided into aliquots. Skin and CSF samples were stored at –80 °C until α -syn RT-QulC analysis was performed.

Genetic studies

Exome and genome sequencing and analysis. ES of individuals A-I-1, A-I-2, A-II-2, C-II-3, D-II-2, I-II-3, L-II-1, M-I-1, M-I-2, M-II-6 was performed by Macrogen (Europe or South Korea) as detailed elsewhere⁷⁴. Briefly, target enrichment was performed with 2 μ g genomic DNA using the SureSelectXT Human All Exon Kit version 6 (Agilent) to generate bar-coded ES libraries. Libraries were sequenced on the HiSeqX platform

(Illumina) with 50x coverage. Quality assessment of the sequence reads was performed by generating QC statistics with FastQC. The bioinformatics filtering strategy included screening for only exonic and donor/acceptor splicing variants. In accordance with the pedigree and phenotype, priority was given to rare variants ($< 0.01\%$ in public databases, including 1000 Genomes project, NHLBI Exome Variant Server, Complete Genomics, and Exome Aggregation Consortium [ExAC v0.2]) that were fitting a recessive (homozygous or compound heterozygous) or a de novo model and/or variants in genes previously linked to movement disorders, neurodevelopmental delay and other neurological disorders. ES of individuals B-II-2, B-II-3, B-II-4, G-II-3 and H-II-1 was performed at the ICM IGenSeq core facility. Exons were captured using the Roche V.3 kit, followed by a massively parallel sequencing on NextSeq500 system (Illumina). Read alignment and variant calling were done using an in-house pipeline. Briefly, FastQC was used to check the quality of the reads and low-quality reads were removed using Trimmomatic. Sequencing data were then aligned to the human reference genome hg19 using the bwa suite36 and variant calling was performed using GATK HaplotypeCaller1. ES data of individuals B-II-2, B-II-3, B-II-4, G-II-3 and H-II-1 were analyzed using VarFT2 software. We filtered all homozygous variants shared by the two affected individuals that possibly affected the cDNA or localized in the splice site region ($-8/+11$ bp from exon/intron junction), with a MAF $< 1\%$ in the gnomAD public database and localized in region of loss of heterozygosity. Genome sequencing (GS) of E-II-4 was performed through the NIH facility. Read alignment and variant calling were done using Dragen version 07.021.624.3.10.4 (Illumina). Research for *PSMF1* variants was done using an in-house R script (https://gitlab.com/icm-institute/corti-corvol/variants_tiers_gene). ES of probands D-II-2, N-II-1 and O-II-2 was carried out by CENTOGENE as previously described⁷⁵, and GS was performed in individual B-II-3 by CENTOGENE as detailed elsewhere⁷⁶. ES of proband F-II-3 was performed using Agilent SureSelect Human All Exon V6 R2 kit with Illumina, NOVA-Seq6000 (Macrogen, South Korea). Raw data obtained from ES were processed using the SEQ platform (Genomize, Istanbul, Turkey). Burrows-Wheeler Aligner (BWA) was used to align with the human reference genome, hg19. Freebayes was applied for variant calling, and the PCR duplicates were removed using the DeDup tool. ES of J-II-1 and J-II-3 was performed as described elsewhere⁷⁷. ES of proband K-II-3 and his parents K-I-1 and K-I-2 were performed on a Novaseq 6000 platform (Illumina, San Diego, California) using IDT xGen Exome Research Panel V2 Kit (Integrated DNA Technologies, Coralville, Iowa). The average read depth was at least 100 reads, and the average percentage coverage of Refseq genes at 20X was at least 94%. The bioinformatic analysis was performed using the Franklin variant interpretation platform (Genoox, Tel Aviv, Israel). Variants were filtered based on their effect on the protein (missense, nonsense, frameshift, splice-site) and a minor allele frequency < 0.01 in general population databases (e.g. gnomAD), and the Rambam Genetics Institute internal database of over 3000 Israeli samples. ES of individual M-II-3 was carried out as reported previously⁷⁸. ES of subjects P-II-5, Q-I-1, Q-I-2 and Q-II-3 was performed as detailed elsewhere⁷⁹. ES of subjects R-I-1, R-I-2 and R-II-2 were carried out as previously reported⁸⁰. Sanger sequencing was used to confirm next-generation sequencing findings and perform family segregation whenever possible. Recommendations of the Human Genome Variation Society were used to describe the cDNA and protein sequence variants using NM_006814.5 and NP_006805.2 as the reference. All next-generation sequencing findings were verified by Sanger sequencing while performing family segregation analysis at the UCL Institute of Neurology or by the referring centers.

Frequency, pathogenicity prediction and computational analysis of *PSMF1* variants. As a reference for potentially neutral variants and frequency of variants in the healthy population, gnomAD (all released versions) was inspected for all identified *PSMF1* variants

(Supplementary Table 1). We also screened the 100,000 Genomes Project, UKB, *All of Us* Public Data Browser, and Queen Square Genomics exome repositories for the *PSMF1* variants identified in our study cohort (Supplementary Table 1). Pathogenicity prediction of *PSMF1* non-splice variants was assessed using CADD, PolyPhen2 HVAR, SIFT4G, PROVEAN, MutationTaster and Human Splicing Finder (HSF) to predict the impact of variants on the protein structure and function (Supplementary Table 1a). To examine the conservation of substituted amino acid positions, we used Genomic Evolutionary Rate Profiling (Supplementary Table 1) and visual multiple sequence alignment of *PSMF1*/hPI31 across multiple different species by inputting *PSMF1*/hPI31 and orthologous protein sequences for each species retrieved from UniProt in Clustal Omega (Fig. 2b)⁸¹. For in silico splice predictions of six splice variants, we used the computational tools SpliceSiteFinder-like, MaxEntScan, NNSPLICE, GeneSplicer, SpliceAI, and AbSplice (Supplementary Table 1b).

Autozygosity mapping. In all affected individuals having homozygous *PSMF1* variants and their unaffected family members with raw ES or GS data available (Pedigrees B-C-D-E-F-G-H-J-L-M-N-O-P), regions of homozygosity ≥ 1 Mb were identified using the AutoMap software (<https://automap.iob.ch/>) by inputting VCF files (Variant Call Format) files (Supplementary Fig. 1)³⁶. Whenever needed, we used UCSC Lift-Over tool for conversion of hg19 VCF files to hg38 prior to perform autozygosity mapping.

Haplotype analysis. Haplotype analysis was performed by plotting a color banding of variants flanking three *PSMF1* variants, each detected in the homozygous state in the affected individuals of two families, including c.724 C > G p.(Arg242Gly) in Pedigrees B-C (B-II-3, B-II-4, C-II-3), c.157 C > A p.(Leu53Met) in Pedigrees F-G (F-II-3, G-II-3), c.764+5 G > A in Pedigrees L-M (L-II-1, M-II-6), and c.691 C > T p.(Arg231*) in Pedigrees N-O (N-II-1, O-II-2). By comparing the banding patterns, the status of being a recurrent or founder variant was investigated. When the banding pattern suggested a founder variant (F-II-3, G-II-3), we supposed the shared region to be an identity-by-descent haplotype and calculated the age of the most recent common ancestor (MRCA) using the ExHap tool (Supplementary Fig. 2)³⁸.

RNA studies

RNA isolation and sequencing. Total RNA was extracted from fibroblasts of proband A-II-2 and his parents (A-I-1, A-I-2) and probands J-II-3, L-II-4 and M-II-6 using the RNeasy Mini Kit (Qiagen) according to the manufacturer's protocol. In J-I-1 and J-I-2, total RNA was isolated from peripheral whole blood treated with red blood cell lysis buffer (Qiagen) and white blood cells were collected for RNA extraction. RNA was extracted using TRIzol™ reagent (Thermo Fisher Scientific, Waltham, Massachusetts, USA) according to manufacturer's instruction. RNA samples with an RNA integrity number (RIN) ≥ 7 was used for RNA-seq. cDNA libraries were prepared by KAPA mRNA HyperPrep Kit (Roche Diagnostics, Tucson, AZ, USA) according to the manufacturer protocol. Briefly, poly-A containing mRNA was collected and fragmented to 200–300 bp. Fragmented mRNA was then used as template for first-strand cDNA synthesis by random hexamer. In the second strand cDNA synthesis, blunt-end double stranded cDNAs were generated for 3' adenylation and indexed adaptor ligation. The adaptor-ligated libraries enriched by polymerase chain reaction were sequenced as 151-bp paired-end runs on Illumina® NovaSeq 6000 platform (Illumina, San Diego, CA, USA) at the Center for PanorOmic Sciences (CPOS), University of Hong Kong. Data cleaning of the transcriptomics profile in fastq format was performed by AfterQC (v0.9.6). The sequence was aligned to the hg19/GRCh37 human reference genome and outputted as bam files using STAR (v2.5.2a, <https://github.com/alexdobin/STAR>) in two-pass mode. RNA sequencing data were processed with DROP v1.3.3 workflow⁸², which integrates the statistical algorithm

OUTRIDER⁸³ and FRASER2^{84,85} for detection of aberrant expression (AE) and aberrant splicing (AS) respectively by computing significant levels of extreme read count values. Briefly, the DROP pipeline enables the systematic detection of AE and AS outliers by comparing an individual's RNA sequencing. AE refers to the differential expression of the two alleles of a gene in a diploid organism. Normally, both alleles are expressed at similar levels. However, one allele can be significantly over- or under-expressed due to coding, non-coding, regulatory, or structural variants. Detecting AE outliers can help identify functional effects of non-coding or regulatory variants, such as promoter or splice mutations. AS refers to abnormal RNA splicing patterns that differ from the expected transcript structure. This can include exon skipping, intron retention, or usage of cryptic splice sites. Since disease-causing variants can disrupt splicing, identifying AS events can reveal the molecular mechanism behind pathogenic variants that may be missed by standard DNA sequencing. Both OUTRIDER⁸³ and FRASER2^{84,85} algorithms utilize a denoising autoencoder to control for the hidden confounder effects. In OUTRIDER for detection of aberrant expression, a false discovery rate (FDR) ≤ 0.05 was used as the cut-off for calling significant aberrant expression outliers⁶⁷. In FRASER2, split reads spanning the exon–exon junction and nonsplit reads spanning the splice sites were counted for splicing event calling. The Intron Jaccard Index is computed using split and non-split reads for capturing several types of aberrant splicing. Significant aberrant splicing events were defined with FDR ≤ 0.1 ^{84,85}.

Minigene splicing assay. When biological material for obtaining RNA was not available, an in vitro assay targeting each exonic region was performed through amplification from genomic DNA to functionally test the predicted impact of *PSMF1* splice variants, as previously described⁸⁶. Primers to assay the *PSMF1* c.365+2 T > C (exon 3) and c.605+1 G > A (exon 5) variants are shown in Supplementary Methods 1. Following amplification, clean-up and restriction enzyme digestion (*XhoI*, *BamHI*) of the PCR amplicon and pSPL3 exon trapping vector was performed prior to ligation between the vector-containing exons A and B of the linearized vector that was transformed into DH5 α competent cells (NEB 5-alpha, New England Biolabs, Frankfurt, Germany), plated and incubated overnight. Colonies with the wild-type containing sequences were selected for correct size using colony PCR with an SD6 forward and the *PSMF1* exon-specific reverse primer. Primers for site-directed mutagenesis were designed with NEBase Changer version 1.3.3 (New England Biolabs, <https://nebasechanger.neb.com/>). Site-directed mutagenesis followed the manufacturer protocol. Clones were selected for overnight LB-amp culture. Plasmids were isolated and Sanger sequence verified. The sequence-confirmed vectors with mutant and wild-type sequence were transfected into HEK293T cells (female donor, ATCC, Manassas, VA, USA) with a density of 2×10^5 cells per mL. 2 μ g of the respective pSPL3 vectors was transiently transfected using 6 μ L of FuGENE 6 Transfection Reagent (Promega, Walldorf, Germany). Empty vector and transfection negative reactions were included as controls. The transfected cells were harvested 24 h after transfection. Total RNA was prepared using miRNAeasy Mini Kit (Qiagen, Hilden, Germany). Approximately 2 μ g of RNA was reverse transcribed using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Thermo Fisher Scientific, Waltham, MA, USA) following the manufacturer protocols. The cDNA was PCR amplified using vector-specific SD6 forward and SA2 reverse primers. Splicing assay could not be performed for the *PSMF1* c.129+2 T > C (exon 1) variant. Since the first exon of a gene does not have a splice acceptor site, we aimed to introduce a variant using site-directed mutagenesis to induce a strong splice acceptor site. However, by permutating the bases around the beginning of exon 1 to each A-T-G-C alternate base, we did not encounter a strong candidate that would have caused a new splice acceptor site to trick exon 1 to be included in the minigene. No sequence in that area resembled branch sequence or a polypyrimidine tract.

Proteomic studies

Protein structure modeling. The crystal structure for the PSMF1/hPI31 homotetramer was accessed through the Protein databank repository, accession number 4OUH⁸⁷. Images were generated using ChimeraX⁸⁸. Structural modeling of the PSMF1/hPI31-FBXO7 heterotetrameric complex was performed using AlphaFold 3³⁸ with primary sequences obtained from UniProt: FBXO7 (Q9Y3I1) and PSMF1/hPI31 (Q92530). Detailed intermolecular interactions were predicted with BIOVIA Discovery Studio Visualizer 2024 using the Non-bond Interaction Monitor. All structures were visualized using PyMOL 3.0.

Western blotting. SH-SY5Y and HepG2 cells were sourced from the American Type Culture Collection (ATCC, RRID:SCR_00167 and HB-8065, respectively). For the Western blotting shown in Fig. 2f, human primary dermal fibroblasts from *PSMF1* probands, their unaffected relatives and healthy controls, in addition to non-targeting siRNA and *PSMF1* siRNA KD SH-SY5Ys were lysed with ice-cold RIPA-lysis buffer consisting of: 50 mM Tris-HCl (pH=7.4), 150 mM NaCl, 1% w/v triton-X-100, 0.5% sodium deoxycholate, 0.1% w/v sodium dodecyl sulphate (SDS), 1x PhosSTOP phosphatase inhibitors and 1x cOmplete™, Mini, EDTA-free Protease Inhibitors (all Sigma Aldrich). 25 µg of protein lysate were separated through SDS polyacrylamide gel electrophoresis (PAGE) using 4–12% NuPAGE Bis-Tris Mini Protein Gels and XCell Sure-Lock Mini Cell (Thermo Fisher Scientific), before transfer to 0.45 µm Immobilon®-FL PVDF membrane (Sigma) using Mini Trans-Blot Cell (Bio-Rad). Blots were blocked with 5% w/v milk in phosphate-buffered saline (PBS) with 0.01% tween-20 (PBST; 1 h, room temperature (RT); Sigma Aldrich). Blots were incubated with the following primary antibodies diluted in 3% w/v milk in PBST (4 °C, overnight): mouse anti-Gapdh IgG2b (1:10000; Abcam Cat# ab110305, RRID:AB_10861081) and rabbit anti-PSMF1/hPI31 IgG (1:1000; Thermo Fisher Scientific/Invitrogen Cat# PA5-21603, RRID:AB_11153838). Blots were then washed 3x with PBST prior to incubation with fluorescently conjugated secondary antibodies diluted in PBST supplemented with 0.02% SDS (2 h, RT): donkey anti-mouse IgG Alexa Fluor Plus 680 (1:40,000; Thermo Fisher Scientific/Invitrogen Cat# A32788, RRID:AB_2762831) and donkey anti-rabbit IgG Alexa Fluor Plus 800 (1:40,000; Thermo Fisher Scientific/Invitrogen Cat# A32808, RRID:AB_2762837). Blots were washed 3x with PBST and 1x with PBS prior to near-infrared (NIR) detection using an Odyssey CLx imager (LI-COR Biosciences, RRID:SCR_014579). For the Western blotting shown in Fig. 2g, protein lysates from HepG2 cells and fibroblasts from either healthy control or proband P-II-5 were isolated using RIPA buffer (Thermo Fisher Scientific Cat# 89900) according to the manufacturer's protocol. 30 µg protein lysates were separated by PAGE (18% gel), semi-dry blotted and incubated with a polyclonal anti-PSMF1/hPI31 IgG Ab (Thermo Fisher Scientific Cat# PA5-21603) at 4 °C overnight. After washing and a 1-h incubation with goat anti-rabbit IgG HRP (Jackson Immuno Research Cat# 111-035-144), the blot was washed again before being developed with ECL-plus (Thermo Fisher Scientific Cat# 32134) for 3 min. After stripping, the same blot was incubated with monoclonal β-actin antibody (Sigma Aldrich Cat# A5441), washed and incubated with rabbit anti-mouse IgG HRP (Jackson Immuno Research Cat# 315-035-045) before being developed for 2 min with ECL-plus.

Quantitative proteomics in human cultured dermal fibroblasts

Sample preparation. Proband- and carrier-derived cultured dermal fibroblasts were harvested in lysis buffer containing 2% SDS (w/v), 100 mM TEAB pH 8.5, with complete EDTA-free protease inhibitor cocktail (Roche) and PhosSTOP phosphatase inhibitor cocktail tablets (Roche). Protein concentrations were determined via BCA assay (Thermo Fisher Scientific) and 5 µg protein aliquoted per sample for proteomic analysis. Samples were reduced with 10 mM TCEP for 30 min at 60 °C, followed by alkylation of cysteine residues with 40 mM IAA for 30 min at room temperature in the dark. 20% SDS was then added to achieve a final concentration of 5% SDS in samples, which were then

acidified by addition of trifluoroacetic acid to a final concentration of 1%. Samples were subsequently processed for on-column tryptic digestion using S-Trap™ micro columns (Protifi, USA)^{89,90}. Briefly, samples were diluted 6x with wash buffer (90% methanol, 10% 100 mM TEABC) and loaded onto micro columns, with centrifugation at 1000 × g for 1 min and flow-through discarded. After sample loading, the S-Trap™ micro columns were washed four times with 150 µl wash buffer followed by centrifugation at 1000 × g, 1 min. On-column digestion was performed by incubating 40 µl (1 µg) of Trypsin/Lys-C mix (MS grade, Promega, UK) in 50 mM TEABC solution (pH 8) at 47 °C for 1 h and 20 min, followed by incubation at 22 °C overnight. The samples were then eluted with addition of 40 µl 50 mM TEABC (pH 8), 40 µl 0.15% (v/v) formic acid (FA), and 3 × 40 µl 80% acetonitrile (ACN), 0.15% FA. Peptides were then dried using a vacuum centrifuge at room temperature and stored at –20 °C until mass spectrometry analysis.

Quantitative proteomic analysis. Peptides were resuspended in 0.1% formic acid supplemented with 0.015% N-Dodecyl-B-D-Maltoside (DDM). 200 ng of peptides were analyzed with a Vanquish Neo nano-liquid chromatography system in-line with an Orbitrap Astral mass spectrometer (Thermo Fisher Scientific). Peptides were trapped and eluted using an Acclaim™ PepMap™ 100 C18 HPLC column (3 µm particle size, 75 µm diameter, 150 mm length) and separated using an EASY-Spray™ PepMap™ Neo UHPLC column (2 µm C18 particle, 75 µm diameter, 150 mm length) with buffer A: 0.1% formic acid and buffer B: 80% ACN, 0.1% formic acid. Peptides were separated across a 13-min gradient, and the data was acquired using narrow window DIA mode. MS1 scans performed at a resolution of 240,000 across a m/z range of 380–980 and measured using ultra-high field orbitrap mass analyzer, with a normalized AGC target of 500% and maximum injection time of 3 milliseconds. DIA scans were performed of the precursor mass range with an isolation window of 4 m/z, scan range of 150–2000 m/z and a normalized collision energy of 25%.

Raw mass spectrometry data analysis. Raw data were searched using DIA-NN (version 1.8.1) against a predicted spectral library generated from the reviewed human UniProt database (downloaded January 2023; 20383 entries with isoforms). Spectra were searched with strict Trypsin specificity (cleavage at K or R residues), allowing a maximum of two missed cleavages. Peptides with an amino acid length of 7–30 were considered. N-terminal methionine excision and oxidation were specified as variable modifications and cysteine carbamidomethylation as a fixed modification, with a maximum of one variable modification permitted.

Statistical analysis and data visualization. Statistical analysis and visualization of DIA-NN output files was performed with Python (version 3.11.5, Jupyter Notebook; Project Jupyter) using packages pandas (2.0.3), matplotlib (3.7.2), seaborn (0.12.2), numpy (1.26.1) and sci-kit learn (1.3.0); before upload to CURTAIN web tool (<https://curtain.proteo.info/#/>, Supplementary Notes 3). Proteins identified by a single peptide were excluded, with log2-transformed protein intensities then filtered by 100% detection in at least one sample condition. Missing values were imputed by random draws from a Gaussian distribution (width 0.3 and downshift 1.8). The Limma package (version 3.56.2; R, version 4.3.1) was used to fit the data to a linear model using the lmfit function, with eBayes correction to compute moderated *t*-statistics and false-discovery rate controlled by Benjamini-Hochberg correction. All mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier: PXD053147⁹¹.

Frequency of *PSMF1* variants in the UK Biobank and accelerating medicines partnership-Parkinson's disease initiative and gene burden

We searched for *PSMF1* missense (nonsynonymous, nonframeshift indels) and loss-of-function (splice, nonsense, frameshift) variants in the

ES data within the UK Biobank (UKB, <https://www.ukbiobank.ac.uk/>)⁹² and extracted exonic variants from GS data from the Accelerating Medicines Partnership-Parkinson's Disease Initiative (AMP-PD, <https://amp-pd.org/>)⁹³. Although we acknowledge the importance of investigating regulatory variants, our analysis focused on coding variants to prioritize those with clearer functional consequences, in line with the objectives of a gene discovery study.

Processing of these cohorts was detailed elsewhere⁹⁴. In brief, the UKB is a large-scale biomedical dataset with clinical and genetic information from ~500,000 participants⁹². After filtering and removing those recruited in a genetic study, the database consists of a total of 45,857 individuals (22,040 males), of which 38,051 are controls, 1,105 cases, 6,033 individuals with a parent that is diagnosed with PD, and 668 individuals with a sibling that is diagnosed with PD (6,701 proxy cases). Among controls, individuals with age at recruitment <59 years, any reported neurological disorders (category 2406 and field codes: Dementia/42018, Vascular dementia/42022, FTD/42024, ALS/42028, Parkinsonism/42030, PD/42032, PSP/42034, MSA/42036), a parent with PD or dementia (field codes: 20107 and 20110) were filtered out^{92,94}.

GS data from multiple datasets, including the Parkinson's Progression Markers Initiative (PPMI), the Parkinson's Disease Biomarkers Program (PDBP), the Harvard Biomarker Study (HBS), BioFIND, SURE-PD3, and STEADY-PD3, were obtained as part of the Accelerating Medicines Partnership in Parkinson's Disease (AMP-PD) initiative. The AMP-PD cohorts (PPMI, PDBP, HBS, BioFIND, SURE-PD3, and STEADY-PD3) followed the GATK Best Practices guidelines established by the Broad Institute's joint discovery pipeline, as well as additional details provided elsewhere⁹³. Data processing and quality control (QC) procedures have been described previously^{93,95}. All individuals included in the analysis were of European ancestry through principal component analysis using HapMap3 European ancestry populations. This selection was motivated by the predominance of genetic data from European individuals in the datasets and was made to ensure consistency and minimize bias due to population stratification. The AMP-PD datasets consist of unrelated individuals and publicly available cohorts only. Similar filtering parameters were used for the AMP-PD databases resulting in a total of 4,007 individuals (2,197 males), with 2,556 being controls and 1,451 being PD cases^{93,94}.

Analyses were restricted to non-familial PD cases, who make up the majority of available data in both cohorts (AMP-PD, UKB). Familial PD cases are limited in number, and their inclusion would have not substantially increased statistical power for this rare-variant analysis. Variants were annotated using ANNOVAR, including the databases refGene, avsnp150, and clinvar_20220320⁹⁶. Variants were then selected/filtered for nonsynonymous (missense), stopgain, stoploss, non-frameshift, frame, splice (loss of function). For both analyses, we applied an upper MAF limit of 0.005, which captured most *PSMF1* variants (Supplementary Notes 2). Raw genotype data files were generated to retrieve information on the allelic status (heterozygous, homozygous for reference allele, homozygous for non-reference allele). Following variant extraction, single variant association tests were performed using PLINK v1.90b4.4 (<http://pngu.mgh.harvard.edu/purcell/plink/>)⁹⁷. To assess whether the average effect of genetic variants in this gene is associated with PD, burden testing was performed using Sequencing Kernel Association optimal unified test (Skat-O), Combined Multivariate and Collapsing (CMC) Wald test and CMC burden testing. This process, including variant annotation using SnpEff and SnpSift softwares, and the Loss-of-Function (LoF) Transcript Effect Estimator (LOFTEE) has been previously described⁹⁴.

α-Synuclein real-time quaking-induced conversion assay

Punch skin biopsies were processed as detailed elsewhere^{98,99}. Briefly, thawed skin samples were washed 3 times in cold 1X PBS and homogenized at 1% (wt/vol) using a gentleMACS Octo Dissociator (Miltenyi

Biotech, Bergisch Gladbach, Germany) in cold 1X PBS supplemented with Complete Protease Inhibitor Mixture (Roche, Basel, Switzerland). Skin homogenates were centrifuged at 1000 × g for 10 min at 4 °C, and supernatants were stored at −80 °C until use. We performed α-syn RT-QuIC as previously described^{39,98,100}. Briefly, we preloaded black 96-well plates with a clear bottom (Nalgene Nunc International, Rochester, NY) with six 0.8-mm silica beads (OPS Diagnostics, Lebanon, NJ) per well. CSF and skin samples were thawed and vortexed before use. For the CSF assay, 15 μL of sample were added as seed to 85 μL of reaction mix containing 40 mM phosphate buffer, pH 8.0, 170 mM NaCl, 10 μM thioflavin-T, 0.0015% sodium dodecyl sulfate, and 0.1 g/L recombinant α-synuclein filtered with a 100-kDa-molecular-weight cutoff filter (Amicon centrifugal filters; Merck Millipore, Burlington, MA). For the skin assay, 2 μL of skin homogenate at 10^{−2} final dilution were added to 98 μL of reaction mix containing 40 mM phosphate buffer, pH 8.0, 170 mM NaCl, 10 μM thioflavin-T, and 0.1 g/L of recombinant α-syn which was produced in house¹⁰⁰. The plate was loaded, sealed with a plate sealer film (Nalgene Nunc International) and incubated into a FLUOstar Omega (BMG LABTECH, Ortenberg, Germany) plate reader at 42 °C with intermittent double-orbital shaking at 400 rpm for 1 min, followed by a 1-min rest. Thioflavin-T fluorescence was measured every 45 min using 450-nm excitation and 480-nm emission filters. We ran 4 replicates per sample. Replicates were deemed positive if at least 2 of the 4 replicates gave a fluorescence signal higher than the positivity threshold, arbitrarily set at 30% of the median *I*_{max} value of the positive control replicates during the 30-h run. RT-QuIC fluorescence responses were analyzed and plotted using GraphPad Prism 9.0 for Windows.

Proteasome activity assays

Native gel analyses were performed to evaluate the relative abundance of different proteasome particles as previously described¹⁹. Five to 10 μg of extracts from *PSMF1* patient-derived fibroblasts and healthy controls dissolved in native sample buffer (Bio-Rad, 1610738) and separated on 3–8 % Criterion XT Tris-Acetate gels (Bio-Rad) under nondenaturing conditions and subsequently transferred onto PVDF membrane for standard Western blot analysis. In parallel, samples were also analyzed by standard Western blot analysis. The different proteasome particles were detected with an anti-20S Alpha7 subunit antibody (Enzo, BML-PW8110) that recognized the 20S core particle and its complexes with 19S regulatory particles (26S). *PSMF1*/hPI31 was detected with either an anti-*PSMF1*/hPI31 antibody Abcam (ab96845) or anti-*PSMF1*/hPI31 antibody Thermo Fisher Scientific/Invitrogen (PA5-21603). β-actin was detected with an anti-β-actin (13E5) antibody (Cell Signaling Technology, 5125S).

Mitochondrial studies in human cultured dermal fibroblasts

Live cell imaging of cultured dermal fibroblasts for studying mitochondrial bioenergetic state and function was performed in cell donors from Pedigrees A-B-F-J-L-M (Fig. 1a). Images were acquired using Zeiss LSM 980 and LSM 710 confocal microscopes equipped with META detection system and 40× oil immersion objective. Images were analyzed using ZEN 2009 software and Fiji 2 software. All statistical analyses and visualizations were conducted using OriginPro 2023 (OriginLab, Northampton, MA, USA).

Measurement of mitochondrial membrane potential (MMP) using TMRM.

For measurements of MMP, dermal fibroblasts plated on 25-mm glass coverslips were loaded for 40 min at room temperature with 25 nM tetramethylrhodamine methylester (TMRM; Invitrogen), a cationic fluorescent dye that enters healthy mitochondria, in a HEPES buffered saline solution (HBSS) composed of 156 mM NaCl, 3 mM KCl, 2 mM MgSO₄, 1.25 mM KH₂PO₄, 2 mM CaCl₂, 10 mM glucose and 10 mM HEPES; pH 7.35. The dye remained present in the media at the time of recording. Confocal images were

obtained using a Zeiss 980 LSM Airy or 710 VIS CLSM equipped with a META detection system and a 40× oil immersion objective. TMRM was excited using the 561 nm laser line and fluorescence was measured above 580 nm. For basal MMP measurements, Z-stack images were obtained by confocal microscopy and analyzed using ZEN 2009 software (Zeiss). TMRM values for control cases were set to 100% and the PSMF1 deficient and family members fibroblasts values were expressed relative to controls. For analysis of response to mitochondrial toxins, images were recorded in a time course-dependent manner from a single focal plane and analyzed using ZEN Zeiss software (Zeiss).

To analyze the maintenance mechanism of MMP, the response to mitochondrial toxins (oligomycin, rotenone FCCP) was studied. TMRM was used in the redistribution mode to assess MMP, and therefore a reduction in TMRM fluorescence represents mitochondrial depolarization. Basal TMRM levels = 100%. TMRM fluorescence after complete depolarization by FCCP = 0%.

Measurement of NADH redox indices. NADH autofluorescence was measured using an epifluorescence inverted microscope equipped with a 20× fluorite objective. Excitation light at a wavelength of 350 nm was provided by a Xenon arc lamp, the beam passing through a monochromator (Cairn Research). Emitted fluorescence light was reflected through a 455 nm long-pass filter to a cooled charge-coupled device (CCD) camera (Retiga; QImaging) and digitized to 12-bit resolution. Imaging data were collected and analyzed using software from Andor. NADH redox indexes and mitochondrial pools were estimated as previously described¹⁰¹.

Dynamics. We further studied the mitochondrial dynamics in the TMRM z-stacks by using the Mitochondrial Network Analysis (MiNA) toolset, a simplified pipeline to analyze the mitochondrial network morphology and fragmentation using fluorescence images and three-dimensional stacks using Fiji 2 software following the creators' protocol¹⁰², we studied the average length of all mitochondrial rods and branches in each cell (Fig. 4f) and the number of branches per network in each cell (Fig. 4g).

Mitophagy. To study mitophagy via mitochondrial and lysosomal colocalization, cells were loaded with 200 nM MitoTracker Green FM and 50 nM LysoTracker Red in HBSS for 30 min before experiments. Confocal images were obtained using a Zeiss 710 confocal microscope equipped with 40X oil immersion objective. The 488 nm argon laser line was used to excite MitoTracker Green fluorescence which was measured between 505 and 530 nm. Illumination intensity was kept to a minimum (about 1% of laser output) to avoid phototoxicity and the pinhole set to give an optical slice of approximately 2 μm. For LysoTracker Red, the 543 nm Ne/He laser line was used with measurement above 650 nm. All data presented were obtained from a minimum of five coverslips and three different cell preparations.

***Drosophila melanogaster* modeling and experiments**

***Drosophila* stocks.** In *Drosophila*, targeted knockdown of *PI3I* and associated positive/negative controls was achieved using the UAS-Gal4 system. We obtained targeted knockdown of *PI3I* expression in conjunction with the UAS-Gal4 system of cell-type-specific transgene expression by RNA-interference (RNAi). Transgenic RNAi flies were generated according to a previously published protocol¹⁰³. Orthologues were identified through the "DIOPT ortholog finder"¹⁰⁴, with *PI3I* (FBgn0033669), *prkn* (FBgn0041100) and *nsmase* (FBgn0035421) being considered as fly orthologues of human *PSMF1*, *PRKN* and *SMPD2*, respectively. Transgenic flies were obtained from the Vienna *Drosophila* Resource Center (VDRC) Stock Center. We crossed the RNAi lines *PI3I* (VDRC ID: 28858), *prkn* (VDRC ID: 47636) and *nsmase* (VDRC ID: 107062) with an nSyb-Gal4 strain to drive pan-neuronal

RNAi expression. Growing flies were exposed to a standard 12 h:12 h light-dark schedule at 25 °C and 60% relative humidity.

Behavioral test (negative geotaxis assay). Adult flies of the selected genotypes were tested for behavioral analyses at Days 10, 20 and 35. Based on previous studies and behavioral tests, *prkn* and *nsmase* were considered as positive and negative control, respectively. We assayed *Drosophila* locomotor activity using the climbing test based on negative-geotaxis analysis. Three experimental replicates were performed, each test including at least 15 flies. The test was performed on all lines five times at each time point after a 1-min rest period. Only females were tested. Flies failing to cross the tube at its midpoint (5-cm) within 10 s from stimulation (repulsion) were interpreted as having a motor impairment. ImageJ software was used to automatically count flies¹⁰⁵. The experiment was performed in triplicate ($n = 3$), with each test including at least 15 flies. All lines were tested five times at each time point, following a 1-min rest period. Only female flies were used in the assay. Flies that did not reach the middle of the tube (5 cm) within 10 seconds after stimulation were considered to exhibit locomotor impairment. Fly counts were automatically performed using ImageJ. Statistical analyses related to the negative geotaxis assay were conducted in R (version 4.1.2) using native packages. Comparisons between two genotypes were performed using the χ^2 (chi-squared) test.

Measurement of mitochondrial membrane potential using TMRM. Flies of the genotype and age indicated were dissected in PBS (Sigma-Aldrich). Whole brains were incubated in 100 nM TMRM in PBS for 30 min, and imaged immediately using a Zeiss LSM 710 confocal microscope with an EC "Plan-Neofluar" 20x/0.50 M27 air objective, taking z-stacks through the entire brain with step sizes of 1–2 μm. Image analyses were performed in ImageJ (version 1.54p): ROIs were drawn around the central brain and mean fluorescence with a background subtraction applied was taken.

Immunostaining and TH+ neuron imaging. Flies of the age and genotype indicated were dissected in PBT. Whole brains were fixed with a 20-min room temperature incubation in 4% paraformaldehyde (MP biomedical) and blocked with a 1-h room temperature incubation in 5% normal goat serum in PBS + 0.3% Triton-X (Sigma-Aldrich). Brains were incubated overnight in primary antibody, washed three times in PBT, and incubated overnight in secondary antibody. Primary antibody was rabbit anti-TH (ab6211, Abcam) at 1:500, and secondary was AlexaFluor Goat anti-rabbit 647 (A-21244, Thermo Fisher Scientific) at 1:1000. Brains were mounted in SlowFade (Thermo Fisher Scientific) and imaged as above. TH+ cell bodies were manually counted in ImageJ while blinded to genotype. Statistical analysis was performed using Graphpad Prism (version 10).

***Mus musculus* modeling and experiments**

Mice. *Psmf1* knockout-first (KOF) mice were bred with a strain expressing FLP1 recombinase to generate a *Psmf1* allele with the third exon flanked by 2 loxP sites (*Psmf1^{fl}* and *Psmf1^{tm1c}*(EUCOMM)Hmgu) as previously described²¹. *Psmf1^{fl/fl}* mice expressed normal levels of *PI3I*, were viable and fertile, and appeared phenotypically normal. However, introduction of a Cre driver successfully inactivated *Psmf1* and resulted in tissue-specific or time-specific loss of *PI3I* protein. UBC-Cre-ERT2 (007001) and Ai14 (007914) mice were purchased from Jackson Laboratories.

Tamoxifen injection. Tamoxifen was dissolved in corn oil overnight at 37 °C to a final concentration of 20 mg/ml. Injection dose was determined by weight, using approximately 75 mg tamoxifen/kg body weight (about 94–100 μl of tamoxifen solution for an adult mouse). Tamoxifen was administered by intraperitoneal injection into 6–7-

week-old mice for 3 consecutive days. During the injection period and for one week after, the mice were monitored for any adverse reaction due to the treatment.

Behavioral tests assessing locomotion and anxiety-related behavior

Rotarod test. We used the rotarod test to assess the motor performance of mice on a rotating accelerating rod (Ugo Basile model). The time-to-fall (rotarod score), i.e., the cumulative time (seconds) a mouse maintained its balance on the rotarod before falling off, was recorded. The maximum latency was set at 300 s per trial. A fall was recorded if the mouse held on to the rod for two consecutive revolutions. Mice treated with tamoxifen or corn oil (controls) started a four-day training period on the rotarod 10 days after the final injection. On day 14 post injection, the time-to-fall for one trial was recorded. The trial was repeated for 10 days to follow the progressive deficit in the tamoxifen treated *Psmf1* UBC-Cre-ERT2 mice. On day 25 post injection, three trials were conducted for each mouse and average latency to fall was determined.

Open field test. We assessed motor activity as a reaction to an unknown environment (anxiety-related behavior). At 26 days post tamoxifen or corn oil injection mice were assayed for locomotion and anxiety in an open field chamber (42 × 42 × 30.5 cm) with a dark enclosure (half of open field chamber) for 10 min. Data were analyzed with Fusion 3.2 software (Open field chamber and software from AccuScan Instruments Inc.). Briefly, mice were moved to testing room 60 min prior to testing to acclimate. Then, mice were placed in the dark enclosure, and activity was recorded for 10 min.

Statistics. We use t-test for pairwise comparisons and one-way ANOVA with Tukey post hoc test for when more than two groups were compared. These were calculated using GraphPad Prism software.

Immunofluorescence of mouse brain sections. At Day 28 after final tamoxifen injection, mice were perfused with PBS followed by 4% paraformaldehyde (PFA) in PBS. Brains were removed and postfixed in 4% PFA PBS overnight at 4 °C. They were then washed in PBS, soaked in 15% sucrose in PBS overnight at 4 °C or until they sank, and then soaked in 30% sucrose in PBS overnight at 4 °C. The brains were embedded in Richard-Allan Scientific Neg-50 Frozen Section Medium, and 50-μm sagittal sections were made using a Leica CM 3050S cryostat. The floating cryostat sections were permeabilized and blocked overnight in PBS with 0.3% Triton X-100 and 5% Normal Donkey Serum (NDS) at 4 °C. The sections were then incubated overnight with primary antibodies diluted in PBS with 0.3% Triton X-100 and 5% NDS. Subsequently, the sections were washed 3 times for 20 min each in PBS with 0.1% Triton X-100 and incubated overnight with Alexa Fluor conjugated secondary antibodies diluted in PBS with 0.3% Triton X-100 and 5% NDS at 4 °C. The sections were then washed for 30 min 4 times in PBS with 0.1% Triton X-100 and mounted with Molecular Probes ProLong Diamond antifade mounting medium. Images were captured on a Zeiss confocal LSM 780 with ZEN software. Primary antibodies used were anti-TH Rb pAb (1/500) Abcam ab112, anti-TH Mouse mAb IgG1κ (clone LNC1) (1/500) Millipore MAB318, GFAP chicken IgY (1/2000) EnCor CPCA-GFAP, GFAP rabbit IgG (1/500) Dako Cytomation Z0334, Iba1 rabbit IgG (1/1000) Wako 019-19741 and SQSTM1/p62 mouse IgG2a (1/500) Abcam ab56416. For the GFAP and Iba1 quantification, percent area in a 45.16 mm squared area of a maximum intensity projection of a confocal stack 6 μm thick for GFAP, 8 μm thick for Iba1 in the deep cerebellar nuclei was determined by thresholding in Fiji (ImageJ) software. This was done for three *Psmf1^{fl/fl}* Ai14/+ UBC-Cre-ERT2/+ mice per treatment, that is corn oil (control) or tamoxifen injected.

Statistics and reproducibility

Statistics for each experiment are provided in the main text, figure legends, supplementary information, and source data file. Sample sizes were not predetermined using statistical methods. All collected human fibroblasts, animal samples, and data points were included in the analyses. Experiments were not randomized. Investigators were aware of human genotypes when performing experiments with human cells or their derivatives and during data analysis. In contrast, investigators were blinded to group genotypes during data acquisition and analysis in all experiments involving *Drosophila* and their derivatives as well as in all experiments involving mice until mouse brain dissection revealed tdTomato fluorescence.

Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

Ethics statement

This research aligns with the Inclusion & ethical guidelines embraced by Nature Communications.

Data availability

All data generated and/or analyzed during this study and used to produce figures, micrographs, graphs, plots and blots are included in the published article, its Supplementary Information, and the accompanying Source Data file. Raw DNA and RNA sequencing data as well as neuroimaging data from the individuals herein reported are securely stored in a controlled-access repository at the UCL Institute of Neurology, University College London, London, UK, and are not publicly available owing to data privacy laws. Next-generation sequencing (NGS) data can be requested from the corresponding authors. Access to these data is subject to ethical restrictions and will be granted only to clinicians and/or researchers who enter into an appropriate research agreement. Access will be restricted to the named recipients, and all NGS data will be anonymized. Quantitative proteomics data generated in this study have been deposited in the CURTAIN web tool (<https://curtain.proteo.info/#/>) under the accession links reported in Supplementary Notes 3. Mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository (<https://www.ebi.ac.uk/pride/archive/projects/PXD053147>) with the dataset identifier PXD053147. Biological materials described in this article, including cell lines, organisms and other reagents, are available from the corresponding authors upon request, subject to completion of any required material transfer agreements (MTAs) and compliance with institutional and legal regulations. For clinical, neuroimaging, genetic, or biological enquiries, please contact Dr Francesca Magrinelli (f.magrinelli@ucl.ac.uk). The expected response time is within 10 working days. Source data are provided with this paper.

References

- Poewe, W. et al. Parkinson disease. *Nat. Rev. Dis. Prim.* **3**, 17013 (2017).
- Dorsey, E. R., Sherer, T., Okun, M. S. & Bloem, B. R. The emerging evidence of the Parkinson pandemic. *J. Parkinsons Dis.* **8**, S3–S8 (2018).
- Trevisan, L. et al. Genetics in Parkinson's disease, state-of-the-art and future perspectives. *Br. Med. Bull.* **149**, 60–71 (2024).
- Morris, H. R., Spillantini, M. G., Sue, C. M. & Williams-Gray, C. H. The pathogenesis of Parkinson's disease. *Lancet* **403**, 293–304 (2024).
- Smolders, S. & Van Broeckhoven, C. Genetic perspective on the synergistic connection between vesicular transport, lysosomal and mitochondrial pathways associated with Parkinson's disease pathogenesis. *Acta Neuropathol. Commun.* **8**, 63 (2020).

6. Bandres-Ciga, S., Diez-Fairen, M., Kim, J. J. & Singleton, A. B. Genetics of Parkinson's disease: An introspection of its journey towards precision medicine. *Neurobiol. Dis.* **137**, 104782 (2020).
7. Prasuhn, J. & Bruggemann, N. Genotype-driven therapeutic developments in Parkinson's disease. *Mol. Med* **27**, 42 (2021).
8. Taymans, J. M. et al. Perspective on the current state of the LRRK2 field. *npj Parkinsons Dis.* **9**, 104 (2023).
9. Bi, M., Du, X., Jiao, Q., Chen, X. & Jiang, H. Expanding the role of proteasome homeostasis in Parkinson's disease: beyond protein breakdown. *Cell Death Dis.* **12**, 154 (2021).
10. Park, J. S., Davis, R. L. & Sue, C. M. Mitochondrial dysfunction in Parkinson's disease: new mechanistic insights and therapeutic perspectives. *Curr. Neurol. Neurosci. Rep.* **18**, 21 (2018).
11. Borsche, M., Pereira, S. L., Klein, C. & Grunewald, A. Mitochondria and Parkinson's disease: clinical, molecular, and translational aspects. *J. Parkinsons Dis.* **11**, 45–60 (2021).
12. Malpartida, A. B., Williamson, M., Narendra, D. P., Wade-Martins, R. & Ryan, B. J. Mitochondrial dysfunction and mitophagy in Parkinson's disease: from mechanism to therapy. *Trends Biochem. Sci.* **46**, 329–343 (2021).
13. Trinh, D., Israwi, A. R., Arathoon, L. R., Gleave, J. A. & Nash, J. E. The multi-faceted role of mitochondria in the pathology of Parkinson's disease. *J. Neurochem* **156**, 715–752 (2021).
14. Chu-Ping, M., Slaughter, C. A. & DeMartino, G. N. Purification and characterization of a protein inhibitor of the 20S proteasome (macropain). *Biochim. Biophys. Acta* **1119**, 303–11 (1992).
15. McCutchen-Maloney, S. L. et al. cDNA cloning, expression, and functional characterization of PI31, a proline-rich inhibitor of the proteasome. *J. Biol. Chem.* **275**, 18557–65 (2000).
16. Uhlen, M. et al. Proteomics. Tissue-based map of the human proteome. *Science* **347**, 1260419 (2015).
17. Zaiss, D. M., Standera, S., Holzthutter, H., Kloetzel, P. & Sijts, A. J. The proteasome inhibitor PI31 competes with PA28 for binding to 20S proteasomes. *FEBS Lett.* **457**, 333–8 (1999).
18. Bader, M. et al. A conserved F box regulatory complex controls proteasome activity in Drosophila. *Cell* **145**, 371–82 (2011).
19. Cho-Park, P. F. & Steller, H. Proteasome regulation by ADP-ribosylation. *Cell* **153**, 614–27 (2013).
20. Liu, K. et al. PI31 Is an Adaptor Protein for Proteasome Transport in Axons and Required for Synaptic Development. *Dev. Cell* **50**, 509–524.e10 (2019).
21. Minis, A. et al. The proteasome regulator PI31 is required for protein homeostasis, synapse maintenance, and neuronal survival in mice. *Proc. Natl. Acad. Sci. USA* **116**, 24639–24650 (2019).
22. Yashiroda, H. et al. N-terminal alpha7 deletion of the proteasome 20S core particle substitutes for yeast PI31 function. *Mol. Cell Biol.* **35**, 141–52 (2015).
23. Yang, B. J. et al. Arabidopsis PROTEASOME REGULATOR1 is required for auxin-mediated suppression of proteasome activity and regulates auxin signalling. *Nat. Commun.* **7**, 11388 (2016).
24. Di Fonzo, A. et al. FBXO7 mutations cause autosomal recessive, early-onset Parkinsonian-pyramidal syndrome. *Neurology* **72**, 240–5 (2009).
25. Kirk, R. et al. Structure of a conserved dimerization domain within the F-box protein Fbxo7 and the PI31 proteasome inhibitor. *J. Biol. Chem.* **283**, 22325–35 (2008).
26. Al Rawi, S. et al. Study of an FBXO7 patient mutation reveals Fbxo7 and PI31 co-regulate proteasomes and mitochondria. *FEBS J.* **291**, 2565–2589 (2024).
27. Vingill, S. et al. Loss of FBXO7 (PARK15) results in reduced proteasome activity and models a Parkinsonism-like phenotype in mice. *EMBO J.* **35**, 2008–25 (2016).
28. Clemen, C. S. et al. VCP and PSMF1: antagonistic regulators of proteasome activity. *Biochem. Biophys. Res. Commun.* **463**, 1210–7 (2015).
29. Scarian, E. et al. The role of VCP mutations in the spectrum of amyotrophic lateral sclerosis-frontotemporal Dementia. *Front. Neurol.* **13**, 841394 (2022).
30. Guo, X. et al. VCP recruitment to mitochondria causes mitophagy impairment and neurodegeneration in models of Huntington's disease. *Nat. Commun.* **7**, 12646 (2016).
31. Sherva, R. et al. Identification of novel candidate genes for Alzheimer's disease by autozygosity mapping using genome wide SNP data. *J. Alzheimers Dis.* **23**, 349–59 (2011).
32. Zhao, L. et al. A rare variant nonparametric linkage method for nuclear and extended pedigrees with application to late-onset Alzheimer disease via WGS data. *Am. J. Hum. Genet.* **105**, 822–835 (2019).
33. Tesson, C. et al. Identification of potential new genes involved in autosomal recessive forms of Parkinson's disease [Abstract number 1113]. in *Proc. International Congress of Parkinson's Disease and Movement Disorders* (Wiley, 2019).
34. Sobreira, N., Schiettecatte, F., Valle, D. & Hamosh, A. Gene-Matcher: a matching tool for connecting investigators with an interest in the same gene. *Hum. Mutat.* **36**, 928–30 (2015).
35. Karczewski, K. J. et al. The mutational constraint spectrum quantified from variation in 141,456 humans. *Nature* **581**, 434–443 (2020).
36. Quinodoz, M. et al. AutoMap is a high performance homozygosity mapping tool using next-generation sequencing data. *Nat. Commun.* **12**, 518 (2021).
37. Alavi, S. ExHap: identifying shared homozygosity haplotypes from multi-sample VCF [Computer software]. (Version 1.0) edn (2025).
38. Abramson, J. et al. Accurate structure prediction of biomolecular interactions with AlphaFold 3. *Nature* **630**, 493–500 (2024).
39. Iranzo, A. et al. Misfolded alpha-synuclein assessment in the skin and CSF by RT-QuIC in isolated REM sleep behavior disorder. *Neurology* **100**, e1944–e1954 (2023).
40. Schapira, A. H. et al. Mitochondrial complex I deficiency in Parkinson's disease. *J. Neurochem.* **54**, 823–7 (1990).
41. Exner, N., Lutz, A. K., Haass, C. & Winklhofer, K. F. Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences. *EMBO J.* **31**, 3038–62 (2012).
42. Pickrell, A. M. & Youle, R. J. The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson's disease. *Neuron* **85**, 257–73 (2015).
43. Burchell, V. S. et al. The Parkinson's disease-linked proteins Fbxo7 and Parkin interact to mediate mitophagy. *Nat. Neurosci.* **16**, 1257–65 (2013).
44. Sanchez-Martinez, A., Martinez, A. & Whitworth, A. J. FBXO7/ntc and USP30 antagonistically set the ubiquitination threshold for basal mitophagy and provide a target for Pink1 phosphorylation in vivo. *PLoS Biol.* **21**, e3002244 (2023).
45. Gandhi, S. et al. PINK1-associated Parkinson's disease is caused by neuronal vulnerability to calcium-induced cell death. *Mol. Cell* **33**, 627–38 (2009).
46. Ludtmann, M. H. R. et al. alpha-synuclein oligomers interact with ATP synthase and open the permeability transition pore in Parkinson's disease. *Nat. Commun.* **9**, 2293 (2018).
47. Abramov, A. Y. et al. Mechanism of neurodegeneration of neurons with mitochondrial DNA mutations. *Brain* **133**, 797–807 (2010).
48. Angelova, P. R. et al. alpha-synuclein fibrils per se but not alpha-synuclein seeded aggregation causes mitochondrial dysfunction and cell death in human neurons. *Redox Biol.* **86**, 103817 (2025).
49. Berezhnov, A. V. et al. Intracellular pH modulates autophagy and mitophagy. *J. Biol. Chem.* **291**, 8701–8 (2016).
50. Komilova, N. R. et al. Metabolically induced intracellular pH changes activate mitophagy, autophagy, and cell protection in familial forms of Parkinson's disease. *FEBS J.* **289**, 699–711 (2022).

51. Brand, A. H. & Perrimon, N. Targeted gene expression as a means of altering cell fates and generating dominant phenotypes. *Development* **118**, 401–15 (1993).
52. Fevga, C. et al. PTPA variants and impaired PP2A activity in early-onset Parkinsonism with intellectual disability. *Brain* **146**, 1496–1510 (2023).
53. Park, J. et al. Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. *Nature* **441**, 1157–61 (2006).
54. Sang, T. K. et al. A Drosophila model of mutant human parkin-induced toxicity demonstrates selective loss of dopaminergic neurons and dependence on cellular dopamine. *J. Neurosci.* **27**, 981–92 (2007).
55. Xie, J., Chen, S., Bopassa, J. C. & Banerjee, S. Drosophila tubulin polymerization promoting protein mutants reveal pathological correlates relevant to human Parkinson's disease. *Sci. Rep.* **11**, 13614 (2021).
56. Whitworth, A. J. et al. Increased glutathione S-transferase activity rescues dopaminergic neuron loss in a Drosophila model of Parkinson's disease. *Proc. Natl. Acad. Sci. USA* **102**, 8024–9 (2005).
57. Ruzankina, Y. et al. Deletion of the developmentally essential gene ATR in adult mice leads to age-related phenotypes and stem cell loss. *Cell Stem Cell* **1**, 113–126 (2007).
58. Madisen, L. et al. A robust and high-throughput Cre reporting and characterization system for the whole mouse brain. *Nat. Neurosci.* **13**, 133–40 (2010).
59. Kam, T. I., Hinkle, J. T., Dawson, T. M. & Dawson, V. L. Microglia and astrocyte dysfunction in parkinson's disease. *Neurobiol. Dis.* **144**, 105028 (2020).
60. MacMahon Copas, A. N., McComish, S. F., Fletcher, J. M. & Caldwell, M. A. The Pathogenesis of Parkinson's Disease: A Complex Interplay Between Astrocytes, Microglia, and T Lymphocytes?. *Front Neurol.* **12**, 666737 (2021).
61. Qian, K. et al. Revisiting the critical roles of reactive astrocytes in neurodegeneration. *Mol. Psychiatry* **28**, 2697–2706 (2023).
62. Wolf, S. A., Boddeke, H. W. & Kettenmann, H. Microglia in physiology and disease. *Annu Rev. Physiol.* **79**, 619–643 (2017).
63. Burda, J. E. & Sofroniew, M. V. Reactive gliosis and the multicellular response to CNS damage and disease. *Neuron* **81**, 229–48 (2014).
64. Quattrone, A. et al. Myocardial 123metaiodobenzylguanidine uptake in genetic Parkinson's disease. *Mov. Disord.* **23**, 21–7 (2008).
65. De Rosa, A. et al. Myocardial (123)I-metaiodobenzylguanidine scintigraphy in patients with homozygous and heterozygous parkin mutations. *J. Nucl. Cardiol.* **24**, 103–107 (2017).
66. Orimo, S. et al. Preserved cardiac sympathetic nerve accounts for normal cardiac uptake of MIBG in PARK2. *Mov. Disord.* **20**, 1350–3 (2005).
67. Brockmann, K. et al. Association between CSF alpha-synuclein seeding activity and genetic status in Parkinson's disease and dementia with Lewy bodies. *Acta Neuropathol. Commun.* **9**, 175 (2021).
68. Zhang, J. et al. Genome-Wide Association Analysis of Neonatal White Matter Microstructure. *Cereb. Cortex* **31**, 933–948 (2021).
69. Hsu, H. C., Wang, J., Kjellgren, A., Li, H. & DeMartino, G. N. High-resolution structure of mammalian PI31-20S proteasome complex reveals mechanism of proteasome inhibition. *J. Biol. Chem.* **299**, 104862 (2023).
70. Rodriguez, J. A. et al. PI31 expression is neuroprotective in a mouse model of early-onset parkinsonism. *Proc. Natl. Acad. Sci.* **122**, e2511899122 (2025).
71. Kraus, F. et al. PARK15/FBXO7 is dispensable for PINK1/Parkin mitophagy in iNeurons and HeLa cell systems. *EMBO Rep.* **24**, e56399 (2023).
72. Lauria, G. et al. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. *Eur. J. Neurol.* **17**, 903–12.e44-9 (2010).
73. Groveman, B. R. et al. Rapid and ultra-sensitive quantitation of disease-associated alpha-synuclein seeds in brain and cerebrospinal fluid by alphaSyn RT-QuIC. *Acta Neuropathol. Commun.* **6**, 7 (2018).
74. Efthymiou, S. et al. Biallelic mutations in neurofascin cause neurodevelopmental impairment and peripheral demyelination. *Brain* **142**, 2948–2964 (2019).
75. Trujillano, D. et al. Clinical exome sequencing: results from 2819 samples reflecting 1000 families. *Eur. J. Hum. Genet.* **25**, 176–182 (2017).
76. Bertoli-Avella, A. M. et al. Successful application of genome sequencing in a diagnostic setting: 1007 index cases from a clinically heterogeneous cohort. *Eur. J. Hum. Genet.* **29**, 141–153 (2021).
77. Kwong, A. K. et al. Exome sequencing in paediatric patients with movement disorders. *Orphanet J. Rare Dis.* **16**, 32 (2021).
78. Han, C. et al. Epileptic encephalopathy caused by mutations in the guanine nucleotide exchange Factor DENND5A. *Am. J. Hum. Genet.* **99**, 1359–1367 (2016).
79. Brunet, T. et al. De novo variants in neurodevelopmental disorders-experiences from a tertiary care center. *Clin. Genet.* **100**, 14–28 (2021).
80. Chen, W. et al. Clinical and molecular characterization of novel FARS2 variants causing neonatal mitochondrial disease. *Mol. Genet. Metab.* **140**, 107657 (2023).
81. Madeira, F. et al. The EMBL-EBI search and sequence analysis tools APIs in 2019. *Nucleic Acids Res.* **47**, W636–W641 (2019).
82. Yepez, V. A. et al. Detection of aberrant gene expression events in RNA sequencing data. *Nat. Protoc.* **16**, 1276–1296 (2021).
83. Brechtman, F. et al. OUTRIDER: a statistical method for detecting aberrantly expressed genes in RNA sequencing data. *Am. J. Hum. Genet.* **103**, 907–917 (2018).
84. Mertes, C. et al. Detection of aberrant splicing events in RNA-seq data using FRASER. *Nat. Commun.* **12**, 529 (2021).
85. Scheller, I. F., Lutz, K., Mertes, C., Yepez, V. A. & Gagneur, J. Improved detection of aberrant splicing with FRASER 2.0 and the intron Jaccard index. *Am. J. Hum. Genet.* **110**, 2056–2067 (2023).
86. Tompson, S.W. & Young, T.L. Assaying the effects of splice site variants by exon trapping in a mammalian cell line. *Bio. Protoc.* **7**, e2281–e2281 (2017).
87. Shang, J., Huang, X. & Du, Z. The FP domains of PI31 and Fbxo7 have the same protein fold but very different modes of protein-protein interaction. *J. Biomol. Struct. Dyn.* **33**, 1528–38 (2015).
88. Meng, E. C. et al. UCSF ChimeraX: Tools for structure building and analysis. *Protein Sci.* **32**, e4792 (2023).
89. Nirujogi, R.S., Fasimoye, R., Phung, T.K. & Alessi, D.R. Protocol for Data Independent Acquisition—Mass spectrometry analysis—a DIA-based Organelle Proteomics. *Proc. Natl. Acad. Sci. USA* <https://doi.org/10.17504/protocols.io.kxygxrkv8j/v1> (2022).
90. Fasimoye, R. et al. Golgi-IP, a tool for multimodal analysis of Golgi molecular content. *Proc. Natl. Acad. Sci. USA* **120**, e2219953120 (2023).
91. Perez-Riverol, Y. et al. The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences. *Nucleic Acids Res.* **50**, D543–D552 (2022).
92. Bycroft, C. et al. The UK Biobank resource with deep phenotyping and genomic data. *Nature* **562**, 203–209 (2018).
93. Iwaki, H. et al. Accelerating medicines partnership: Parkinson's disease. Genetic resource. *Mov. Disord.* **36**, 1795–1804 (2021).

94. Makarious, M. B. et al. Large-scale rare variant burden testing in Parkinson's disease. *Brain* **146**, 4622–4632 (2023).
95. Bandres-Ciga, S. et al. Large-scale pathway specific polygenic risk and transcriptomic community network analysis identifies novel functional pathways in Parkinson disease. *Acta Neuropathol.* **140**, 341–358 (2020).
96. Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. *Nucleic Acids Res.* **38**, e164 (2010).
97. Purcell, S. et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am. J. Hum. Genet.* **81**, 559–75 (2007).
98. Mammana, A. et al. RT-QulC detection of pathological alpha-synuclein in skin punches of patients with Lewy body disease. *Mov. Disord.* **36**, 2173–2177 (2021).
99. Mammana, A. et al. Detection of prions in skin punch biopsies of Creutzfeldt-Jakob disease patients. *Ann. Clin. Transl. Neurol.* **7**, 559–564 (2020).
100. Rossi, M. et al. Ultrasensitive RT-QulC assay with high sensitivity and specificity for Lewy body-associated synucleinopathies. *Acta Neuropathol.* **140**, 49–62 (2020).
101. Barilani, M. et al. Age-related changes in the energy of human mesenchymal stem cells. *J. Cell Physiol.* **237**, 1753–1767 (2022).
102. Valente, A. J., Maddalena, L. A., Robb, E. L., Moradi, F. & Stuart, J. A. A simple ImageJ macro tool for analyzing mitochondrial network morphology in mammalian cell culture. *Acta Histochem.* **119**, 315–326 (2017).
103. Qiao, H. H. et al. An efficient and multiple target transgenic RNAi technique with low toxicity in *Drosophila*. *Nat. Commun.* **9**, 4160 (2018).
104. Hu, Y. et al. An integrative approach to ortholog prediction for disease-focused and other functional studies. *BMC Bioinform.* **12**, 357 (2011).
105. Schneider, C. A., Rasband, W. S. & Eliceiri, K. W. NIH Image to ImageJ: 25 years of image analysis. *Nat. Methods* **9**, 671–5 (2012).
106. Kahraman, D., Eggers, C., Schicha, H., Timmermann, L. & Schmidt, M. Visual assessment of dopaminergic degeneration pattern in 123I-FP-CIT SPECT differentiates patients with atypical Parkinsonian syndromes and idiopathic Parkinson's disease. *J. Neurol.* **259**, 251–60 (2012).
107. Yates, A. D. et al. Ensembl 2026. *Nucleic Acids Res.* **54**, D1053–D1060 (2026).

Acknowledgements

For their work on this study: Fr. Ma. was supported by the Edmond J. Safra Fellowship in Movement Disorders, the Edmond J. Safra Movement Disorders Research Career Development Award (Grant ID: MJFF-023893), Parkinson's UK (Grant ID: G-2401), the American Parkinson Disease Association (Grant ID: 1282403), the NIHR UCLH BRC Translational Neuroscience Intermediate Fellowship (Grant ID: BRC1287/TN/FM/101410) and the David Pearlman Charitable Foundation. Cr. Te. received funding from the program "Investissements d'avenir" ANR-10-IAIHU-06. Cr. Te., Th. Co., Cl. Pi., Ma. Ca., Ba. A. Ha., Gu. Co., Su. Le., and Al. Br. were supported by the RMF through the project "DBS - From genetic mutations to motor circuit dysfunctions & recovery". Be. O'C. was supported by a post-doctoral non-clinical fellowship from the Guarantors of Brain. Si. A. Lo and Ja. CE. Je. were funded by an MRC Senior Non-Clinical Fellowship (MR/V03118X/1) and a BBSRC Project Grant (BB/X00094X/1). Ai.Sa. was supported by La Caixa Postgraduate Abroad fellowship. Ba. Vo. was funded by the German Research Foundation DFG VO 2138/7-1 grant 469177153. No. Es. was supported by a Ramón y Cajal Fellowship RYC2021-034267-I and a research grant PID2022-137011OA-I00 funded by the Spanish Ministry of Science and the European Union. Pa. A. Le. was supported by a Royal Society Industry Fellowship (IF\R2\222002) with LifeArc technologies. St. Ef. was supported by an MRC strategic

award to establish an International Centre for Genomic Medicine in Neuromuscular Diseases (ICGNMD) MR/S005021/1'. Re. Bu., Ta. Fr., and Li. So. were supported by the German Academic Exchange Service (DAAD) as part of the German-Arab Transformation Program Line 4 (Project-ID 57166498). Re. Bu. was supported by Deutsche Forschungsgemeinschaft (German Research Foundation, DFG, grant number BU 3602/1-1). Gu. Co. was supported by the Global Parkinson's Genetics Program (GP2), which is funded by the Aligning Science Across Parkinson's (ASAP) initiative and implemented by The Michael J. Fox Foundation for Parkinson's Research (<https://gp2.org>; Grant ID: MJFF-024876). Tu. Gü. and Ay. N. Ba. were supported by Suna and İnan Kırac Foundation and Koç University School of Medicine, Istanbul, Turkey. Mi. Ze. received research support from the German Research Foundation (DFG 458949627; ZE 1213/2-1). Mi. Ze. acknowledges grant support by the European Joint Programme on Rare Diseases (EJP RD Joint Transnational Call 2022), and the German Federal Ministry of Education and Research (BMBF, Bonn, Germany), awarded to the project PreDyT (PREdictive biomarkers in DYsTonia, 01GM2302), by the Federal Ministry of Education and Research (BMBF) and the Free State of Bavaria under the Excellence Strategy of the Federal Government and the Länder, as well as by the Technical University of Munich – Institute for Advanced Study. Mi. Ze.'s research is also supported by a "Schlüsselprojekt" grant from the Else Kröner-Fresenius-Stiftung (2022_EKSE.185). Vi. Bo. received financial support from the Stichting Parkinson Fonds, The Netherlands, Grant. n. 1880. To. B. Ha. received funding from the European Commission (Recon4IMD - GAP-101080997) and the European Health and Digital Executive Agency (HADEA) for the European Rare Disease Research Alliance (ERDERA, grant agreement 101156595). Part of this study (Br. Ch., An. Kw., Ma. Ch., Ea. Ng., and Sz. Fa.) was supported by the Society for the Relief of Disabled Children (SRDC) and the Commissioned Paediatric Research at Hong Kong Children Hospital (PR-HKU-4) under the Health and Medical Research Fund (HMRF) by the Hong Kong Food and Health Bureau. Jo.A.Ha. and He.Ho. are grateful for the important support from patients and families, our UK and international collaborators, brainbank and biobanks, and grateful for essential funding from The Wellcome Trust, The MRC, The MSA Trust, UK Dementia Research Institute, The National Institute for Health Research University College London Hospitals Biomedical Research Centre NIHR-BRC), The Michael J Fox Foundation (MJFF), The Fidelity Foundation, Rosetrees Trust, EAN, ERDERA: European Union's Horizon Europe research and innovation programme, The Dolby Family Fund, Alzheimer's Research UK (ARUK), Mission MSA, Defeat MSA, Parkinson's disease UK, Parkinson's Foundation, Muscular Dystrophy UK, Ataxia UK, CureDRPLA, ALS Association, National Ataxia Foundation (NAF), Target ALS Foundation, Medical Research Foundation and The National Brain Appeal. This research was supported in part by the Intramural research Program of the NIH, National institute on Aging. Part of this work was supported by grants from the Cure Alzheimer's Fund and The Pershing Square Foundation to He. St. Su. Le. received grants from Fondation pour la Recherche Médicale (FRM, MND202004011718), la Fondation de France, France-Parkinson Association, la Fédération pour la Recherche sur le Cerveau (FRC) and the French program "Investissements d'avenir" (ANR-10-IAIHU-06). Other authors do not have funding to declare. The authors thank Dr Andrew B. Singleton (National Institutes of Health, Bethesda, USA), Prof. Manju Kurian and Dr Zane Jaunmuktane (University College London, London, United Kingdom), Prof. Olaf Riess and Dr German Demidov (University of Tübingen, Tübingen, Germany), Dr Julia Baptista (Exeter Genomics Laboratory, Exeter, United Kingdom), Dr Erin Torti (GeneDx), Dr Jill Anne Mokry (Baylor Genetics), Prof. Stephan Züchner (University of Miami, Miami, USA), Dr Khadijah Bakur and Dr Fowzan Alkuraya (Lifera Omics), Dr Rami Abou Jamra (University of Leipzig, Leipzig, Germany), Dr Nikola Kresojević (University Clinical Center of Serbia, Belgrade, Serbia), Dr Michele Matarazzo (HM CINAC, Madrid, Spain), Prof. Naci Karaağaç (Istanbul University, Istanbul, Turkey), Dr Bernd Wilken (Klinikum Kassel, Kassel, Germany), Dr Laura Mahoney

Sanchez (The Francis Crick Institute, London, United Kingdom), Prof. Christine Klein, Dr Joanne Trinh and Dr Manu Sharma (University of Lübeck, Lübeck, Germany). Cr. Te., Th. Co., Cl. Pi., Ma. Ca., Ba. A. Ha., Gu. Co., Su. Le., and Al. Br. thank the DNA and cell bank of the ICM, Sorbonne Université, Paris, France, for sample preparation and acknowledge that part of this work was carried out on the iGenSeq and DAC core facilities of the ICM. Jo. Ro., Ju. Sh., Ma. Vo., and He. St. thank Beily Durbin for her logistical support to the study. Ed. Mo. Fr. Ca., Ma. Sa., and Al. DF. thank Dr Giulia Di Rauso and Dr Valentina Fioravanti (Neurology Unit, Azienda USL-IRCCS of Reggio Emilia, Reggio Emilia, Italy), and Dr Stefano Amidei and Dr Giombattista Sallemi (Department of Neurology, Carpi Hospital, Modena, Italy). Tu. Gü. and Ay. N. Ba. gratefully acknowledge Suna and İnan Kırac Foundation and the use of the services and facilities of the Koç University Research Center for Translational Medicine (KUTTAM), Istanbul, Turkey. Ni.Ba. thanks Dr Gordana Mustač (Zadar General Hospital, Zadar, Croatia). Ch. Fa. and To. B. Ha. are members of the European Reference Network on Rare Congenital Malformations and Rare Intellectual Disability ERN-ITHACA (EU Framework Partnership Agreement ID: 3HP-HP-FPA ERN-01-2016/739516). Mi. Ze. is a member of the Medical and Scientific Advisory Council of the Dystonia Medical Research Foundation and a member of the Governance Council of the International Cerebral Palsy Genomics Consortium. He. Ho. thanks Prof. Vincenzo Salpietro (University of L'Aquila, L'Aquila, Italy). The following genetic databases were used or screened: human reference genomes hg19 and hg38, ClinVar, The UK's 100,000 Genomes Project, Solve-RD, CENTOGENE, GeneDx, Baylor Genetics, Genesis, LiferA Omics. We gratefully acknowledge *All of Us* participants for their contributions, without whom part of this research would not have been possible. We also thank the National Institutes of Health's *All of Us* Research Program for making available the Public Data Browser (Genomic Variants) screened in this study. We used data from the UK Biobank Resource under Application Number 33601. This study used the high-performance computational capabilities of the Biowulf Linux cluster at the National Institutes of Health (<http://hpc.nih.gov>). Data used in the preparation of this article were obtained from the AMP-PD Knowledge Platform. For up-to-date information on the study, visit <https://www.amp-pd.org>. AMP-PD—a public–private partnership—is managed by the FNIH and funded by Celgene, GSK, the Michael J. Fox Foundation for Parkinson's Research, the National Institute of Neurological Disorders and Stroke, Pfizer, and Verily. We thank AMP-PD for the publicly available GS data, including cohorts from the Fox Investigation for New Discovery of Biomarkers (BioFIND), the Parkinson's Progression Markers Initiative (PPMI), and the Parkinson's Disease Biomarkers Program (PDBP). The Parkinson's Disease Biomarker Program (PDBP) consortium is supported by the National Institute of Neurological Disorders and Stroke (NINDS) at the National Institutes of Health. A full list of PDBP investigators can be found at <https://pdbp.ninds.nih.gov/policy>. Harvard Biomarker Study (HBS) is a collaboration of HBS investigators (full list of HBS investigators found at <https://www.bwhparkinsoncenter.org/biobank>) and funded through philanthropy and NIH, and Non-NIH funding sources. The HBS Investigators have not participated in reviewing the data analysis or content of the manuscript. This research was made possible through access to data in the National Genomic Research Library, which is managed by Genomics England Limited (a wholly owned company of the Department of Health and Social Care). The National Genomic Research Library holds data provided by patients and collected by the NHS as part of their care and data collected as part of their participation in research. The National Genomic Research Library is funded by the National Institute for Health Research and NHS England. The Wellcome Trust, Cancer Research UK and the Medical Research Council have also funded research infrastructure. The data used for the analysis of *PSMF1* transcripts described in this manuscript were obtained from the GTEx Portal (GTEx Transcript Browser) on 18 July 2025.

Author contributions

Fr. Ma. conceived the study and led data generation, analysis, interpretation, and manuscript preparation. Ch. Te., Pl. R. An., Jo. A. Ro., An. Sc., Be. O'C., Si. A. Lo., Ma. Ja., Ba. Vo., No. Es., An. Ma., Ju. Sh., An. K. Kw., Th. Co., Va. Pi., Ma. B. Ma., and Si. Ba. contributed to data generation, analysis, interpretation, and manuscript preparation. Ai. Sa., Sh. AL, Re. Bu., Li. So., Gu. J. Br., Da. Mu., Ma. Vo., and Ro. St. contributed to data generation. Br. H. Ch., Re. Ma., Ra. Ni., Ma. Se., Ed. Mo., Cl. Ro., Pa. A. Le., St. Ef., Pa. Li., Ch. Pi., Ma. M. Ch., Sa. If., and Mi. Ze. contributed to data analysis. Ma. Sv., Be. Sa., Ha. A. Ha., Ba. Bi., Fr. Ca., Ma. Sa., Jo. A. Ob., Mo. M. Ku., Gu. Co., Gü. Ki., Tu. Gü., Hü. Ti., Gü. A. Yü., Gü. Ya., Bü. El., Ni. Ba., Ea. W. Ng., Sz. Fa., To. He., Ka. We., Ja. R. AL, Ti. Su., Is. A. AL, Ta. Fr., Ha. Ab., Mu. N. An., An. Sa., Hu. A. Ch., Ch. Fa., Ul. A. Sc., Th. Zö., Ka. St., and Vi. Va. contributed clinico-radiological data. Ma. Ca., Ba. A. Ha., Pe. Ba., Mi. Ti., So. Ga., Co. Bl., Jo. A. Ha., Al. DF., Vi. Bo., To. B. Ha., Ai. M. Be., Su. Le., Ay. N. Ba., and the *PSMF1* Study Group contributed to manuscript revision. Pi. Pa., Ja. E. Je., Da. R. AL, Al. Br., He. St., An. Y. Ab., Ka. P. Bh., and He. Ho. contributed to data interpretation and manuscript revision. Al. Br. and He. St. contributed equally as co-second-last authors. All authors contributed to the discussion and approved the final manuscript.

Competing interests

Pr. A. Le. acts as a paid consultant for Serna Bio. Mo. M. Ku. has received speaking and lecture fees by the International Parkinson and Movement Disorder Society, the World Parkinson Coalition, BIAL, Zambon, Esteve, Consulting for Elsevier Health Iberica, BIAL, UCB and Gondola Medical Technologies as well as funding grants from Research and Innovation Quiron Salud and EU Horizon 2023. Vi. Bo. has received research grants from the Stichting ParkinsonFonds, a research grant from Alzheimer Nederland and honoraria from Elsevier Ltd, for serving as co-Editor-in-Chief of Parkinsonism & Related Disorders. Sa. If., Pe. Ba., and Ai. M. Be. are employed by CENTOGENE GmbH. Ka.P.Bh. receives royalties from publication of the Oxford Specialist Handbook Parkinson's Disease and Other Movement Disorders (Oxford University Press, 2008), of Marsden's Book of Movement Disorders (Oxford University Press, 2012), and of Case Studies in Movement Disorders - Common and uncommon presentations (Cambridge University Press, 2017). Ka. P. Bh. has received honoraria/personal compensation for participating as consultant/scientific board member from Ipsen, Allergan, Merz and honoraria for speaking at meetings from Allergan, Ipsen, Merz, Sun Pharma, Teva, UCB Pharmaceuticals and from the American Academy of Neurology and the International Parkinson's Disease and Movement Disorders Society. All remaining authors do not have competing financial or non-financial interests as defined by Nature Portfolio.

Additional information

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41467-026-71351-w>.

Correspondence and requests for materials should be addressed to Francesca Magrinelli, Kailash P. Bhatia or Henry Houlden.

Peer review information *Nature Communications* thanks the anonymous reviewers for their contribution to the peer review of this work. A peer review file is available.

Reprints and permissions information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc-nd/4.0/>.

© The Author(s) 2026

Francesca Magrinelli¹✉, **Christelle Tesson**^{2,58}, **Plamena R. Angelova**^{1,58}, **Jose A. Rodriguez**^{3,58}, **Annarita Scardamaglia**^{4,58}, **Benjamin O'Callaghan**^{5,58}, **Simon A. Lowe**^{6,58}, **Ainara Salazar-Villacorta**^{4,58}, **Brian Hon-Yin Chung**^{7,8,58}, **Matthew Jaconelli**⁹, **Barbara Vona**^{10,11}, **Noemi Esteras**^{1,12,13}, **Angela Mammana**¹⁴, **Junko Shimazu**³, **Anna Ka-Yee Kwong**⁷, **Thomas Courtin**², **Shahryar Alavi**⁵, **Reza Maroofian**⁴, **Raja Nirujogi**⁹, **Mariasavina Severino**¹⁵, **Edoardo Monfrini**¹⁶, **Clarissa Rocca**⁴, **Patrick A. Lewis**^{5,17}, **Stephanie Efthymiou**⁴, **Rebecca Buchert**¹⁸, **Linda Sofan**¹⁸, **Pawel Lis**⁹, **Chloé Pinon**², **Guido J. Breedveld**¹⁹, **Martin Man-Chun Chui**⁷, **David Murphy**¹, **Vanessa Pitz**²⁰, **Mary B. Makarios**²¹, **Simone Baiardi**^{14,22}, **Marina Volin**³, **Marlene Cassar**², **Bassem A. Hassan**², **Sana Iftikhar**²³, **Peter Bauer**²⁴, **Michele Tinazzi**²⁵, **Marina Svetel**²⁶, **Bedia Samanci**²⁷, **Haşmet A. Hanağası**²⁷, **Basar Bilgiç**²⁷, **Francesco Cavallieri**²⁸, **Mario Santangelo**²⁹, **José A. Obeso**^{13,30,31}, **Monica M. Kurtis**³², **Guillaume Cogan**², **Güneş Kiziltan**³³, **Tuğçe Gül-Demirkale**³⁴, **Hülya Tireli**³⁵, **Gülbün A. Yüksel**³⁶, **Gül Yalçın-Cakmaklı**³⁷, **Bülent Elibol**³⁷, **Nina Barišić**³⁸, **Earny Wei-Sen Ng**⁷, **Sze-Shing Fan**⁷, **Tova HersHKovitz**³⁹, **Karin Weiss**^{40,41}, **Javeria Raza Alvi**⁴², **Tipu Sultan**⁴², **Issam Azmi Alkhawaja**⁴³, **Tawfiq Froukh**⁴⁴, **Hadeel Abdollah E. Alrukban**⁴⁵, **Muhammad Nadeem Anjum**⁴⁶, **Anjum Saeed**⁴⁶, **Huma Arshad Cheema**⁴⁶, **Christine Fauth**⁴⁷, **Ulrich A. Schatz**^{47,48}, **Thomas Zöggeler**⁴⁹, **Michael Zech**^{48,50,51}, **Karen Stals**⁵², **Vinod Varghese**⁵³, **Sonia Gandhi**^{1,54}, **Cornelis Blauwendraat**^{20,55}, **John A. Hardy**⁵, **Alessio Di Fonzo**¹⁶, **Vincenzo Bonifati**¹⁹, **Tobias B. Haack**^{18,48}, **Aida M. Bertoli-Avella**²⁴, **Suzanne Lesage**², **Ayşe Nazlı Başak**³⁴, **Robert Steinfeld**^{56,57}, **Piero Parchi**^{14,22}, **James E. C. Jenson**⁶, **Dario R. Alessi**⁹, **PSMF1 Study Group***, **Alexis Brice**², **Hermann Steller**³, **Andrey Y. Abramov**^{1,59}, **Kailash P. Bhatia**^{1,59}✉ & **Henry Houlden**^{4,59}✉

¹Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, University College London, London, UK. ²Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, APHP, Hôpital de la Pitié Salpêtrière, Paris, France. ³Strang Laboratory of Apoptosis and Cancer Biology, The Rockefeller University, New York, NY, USA. ⁴Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, University College London, London, UK. ⁵Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, UK. ⁶Research Department of Epilepsy, UCL Queen Square Institute of Neurology, University College London, London, UK. ⁷Department of Paediatrics and Adolescent Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China. ⁸Hong Kong Genome Institute, Hong Kong SAR, China. ⁹Medical Research Council (MRC) Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of Dundee, Dundee, UK. ¹⁰Institute of Human Genetics, University Medical Center Göttingen, Göttingen, Germany. ¹¹Institute for Auditory Neuroscience and Inner Ear Lab, University Medical Center Göttingen, Göttingen, Germany. ¹²Neurochemistry Research Institute, Department of Biochemistry and Molecular Biology, School of Medicine, Complutense University of Madrid, Madrid, Spain. ¹³CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, Madrid, Spain. ¹⁴IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy. ¹⁵Neuroradiology Unit, IRCCS Istituto Giannina Gaslini, Genova, Italy. ¹⁶Neurology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. ¹⁷Royal Veterinary College, London, UK. ¹⁸Institute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany. ¹⁹Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam, The Netherlands. ²⁰Integrative Neurogenetics Unit, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA. ²¹Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA. ²²Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy. ²³Department of Real-World evidence studies, CENTOGENE GmbH, Rostock, Germany. ²⁴Department of Medical Genetics, CENTOGENE GmbH, Rostock, Germany. ²⁵Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy. ²⁶Movement Disorders Department, Neurology Clinic, University Clinical Center of Serbia, Belgrade, Serbia. ²⁷Behavioral Neurology and Movement Disorders Unit, Department of Neurology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey. ²⁸Neurology Unit, Neuromotor and Rehabilitation Department, Azienda USL-IRCCS of Reggio Emilia, Reggio Emilia, Italy. ²⁹Department of Neurology, Carpi Hospital, Carpi, Italy. ³⁰HM CINAC, Hospital Universitario HM Puerta del Sur, HM Hospitales, Madrid, Spain. ³¹University CEU-San Pablo, Madrid, Spain.

³²Neurology Department, Hospital Ruber Internacional, Madrid, Spain. ³³Department of Neurology, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey. ³⁴Research Center for Translational Medicine - Neurodegeneration Research Laboratory (KUTTAM-NDAL), School of Medicine, Koç University, Istanbul, Turkey. ³⁵Vocational School, İstanbul Nisantasi University, Istanbul, Turkey. ³⁶Department of Neurology, Haydarpasa Numune Training and Research Hospital, University of Health Sciences, Istanbul, Turkey. ³⁷Department of Neurology, School of Medicine, Hacettepe University, Ankara, Turkey. ³⁸University of Zagreb Medical School, Department of Pediatric Clinical Medical Centre Split, Polyclinic Aviva Zagreb, Zagreb, Croatia. ³⁹The Genetics Institute, Galilee Medical Center, Nahariya, Israel. ⁴⁰Genetics Institute, Rambam Health Care Center, Haifa, Israel. ⁴¹Ruth and Bruce Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel. ⁴²Department of Paediatric Neurology, The Children's Hospital and the University of Child Health Sciences, Lahore, Pakistan. ⁴³Pediatric Neurology Unit, Pediatric Department, Albashir Hospital, Amman, Jordan. ⁴⁴Department of Biotechnology and Genetics Engineering, Philadelphia University, Amman, Jordan. ⁴⁵Department of Pediatrics, Prince Sultan Military Medical City, Riyadh, Saudi Arabia. ⁴⁶Department of Gastroenterology, Hepatology and Nutrition, The Children's Hospital and the University of Child Health Sciences, Lahore, Pakistan. ⁴⁷Institute of Human Genetics, Medical University Innsbruck, Innsbruck, Austria. ⁴⁸Institute of Human Genetics, School of Medicine and Health, Technical University of Munich, Munich, Germany. ⁴⁹Department of Pediatrics I, Medical University Innsbruck, Innsbruck, Austria. ⁵⁰Institute of Neurogenetics, Helmholtz Zentrum Munich, Munich, Germany. ⁵¹Institute for Advanced Study, Technical University of Munich, Garching, Germany. ⁵²Exeter Genomics Laboratory, Royal Devon University Healthcare NHS Foundation Trust, Exeter, UK. ⁵³All Wales Medical Genomics Service, Cardiff, UK. ⁵⁴Neurodegeneration Biology Laboratory, The Francis Crick Institute, London, UK. ⁵⁵Center for Alzheimer's and Related Dementias (CARD), National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA. ⁵⁶Department of Pediatrics and Pediatric Neurology, University of Göttingen, Göttingen, Germany. ⁵⁷Department of Pediatric Neurology, Charité University Medicine, Berlin, Germany. ⁵⁸These authors contributed equally: Christelle Tesson, Plamena R. Angelova, Jose A. Rodriguez, Annarita Scardamaglia, Benjamin O'Callaghan, Simon A. Lowe, Ainara Salazar-Villacorta, Brian Hon-Yin Chung. ⁵⁹These authors jointly supervised this work: Andrey Y. Abramov, Kailash P. Bhatia, Henry Houlden. ✉ e-mail: f.magrinelli@ucl.ac.uk; francescamagrinelli@gmail.com; k.bhatia@ucl.ac.uk; h.houlden@ucl.ac.uk

PSMF1 Study Group

Francesca Magrinelli¹✉, Christelle Tesson^{2,58}, Plamena R. Angelova^{1,58}, Jose A. Rodriguez^{3,58}, Annarita Scardamaglia^{4,58}, Benjamin O'Callaghan^{5,58}, Simon A. Lowe^{6,58}, Ainara Salazar-Villacorta^{4,58}, Brian Hon-Yin Chung^{7,8,58}, Matthew Jaconelli⁹, Barbara Vona^{10,11}, Noemi Esteras^{1,12,13}, Angela Mammana¹⁴, Junko Shimazu³, Anna Ka-Yee Kwong⁷, Thomas Courtin², Shahryar Alavi⁵, Reza Maroofian⁴, Raja Nirujogi⁹, Mariasavina Severino¹⁵, Edoardo Monfrini¹⁶, Clarissa Rocca⁴, Patrick A. Lewis^{5,17}, Stephanie Efthymiou⁴, Rebecca Buchert¹⁸, Linda Sofan¹⁸, Pawel Lis⁹, Chloé Pinon², Guido J. Breedveld¹⁹, Martin Man-Chun Chui⁷, David Murphy¹, Vanessa Pitz²⁰, Mary B. Makarious²¹, Simone Baiardi^{14,22}, Marina Volin³, Marlene Cassar², Bassem A. Hassan², Sana Iftikhar²³, Peter Bauer²⁴, Michele Tinazzi²⁵, Marina Svetel²⁶, Bedia Samanci²⁷, Haşmet A. Hanağası²⁷, Basar Bilgiç²⁷, Francesco Cavallieri²⁸, Mario Santangelo²⁹, José A. Obeso^{13,30,31}, Monica M. Kurtis³², Guillaume Cogan², Güneş Kiziltan³³, Tuğçe Gül-Demirkale³⁴, Hülya Tireli³⁵, Gülbün A. Yüksel³⁶, Gül Yalçın-Cakmaklı³⁷, Bülent Elibol³⁷, Nina Barišić³⁸, Earny Wei-Sen Ng⁷, Sze-Shing Fan⁷, Tova HersHKovitz³⁹, Karin Weiss^{40,41}, Javeria Raza Alvi⁴², Tipu Sultan⁴², Issam Azmi Alkhawaja⁴³, Tawfiq Froukh⁴⁴, Hadeel Abdollah E. Alrukban⁴⁵, Muhammad Nadeem Anjum⁴⁶, Anjum Saeed⁴⁶, Huma Arshad Cheema⁴⁶, Christine Fauth⁴⁷, Ulrich A. Schatz^{47,48}, Thomas Zöggeler⁴⁹, Michael Zech^{48,50,51}, Karen Stals⁵², Vinod Varghese⁵³, Sonia Gandhi^{1,54}, Cornelis Blauwendraat^{20,55}, John A. Hardy⁵, Alessio Di Fonzo¹⁶, Vincenzo Bonifati¹⁹, Tobias B. Haack^{18,48}, Aida M. Bertoli-Avella²⁴, Suzanne Lesage², Ayşe Nazlı Başak³⁴, Robert Steinfeld^{56,57}, Piero Parchi^{14,22}, James E. C. Jepson⁶, Dario R. Alessi⁹, Alexis Brice², Hermann Steller³, Andrey Y. Abramov^{1,59}, Kailash P. Bhatia^{1,59}✉ & Henry Houlden^{4,59}✉

A full list of members and their affiliations appears in the Supplementary Information.